

CERTIFICATION UNDER 37 CFR 1.10

09/171697

EL163085359US


23 OCT 1998

Express Mail Mailing Number

Date of Deposit

I hereby certify that this paper or fee, and any documents referred to as enclosed herein, are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Box PCT, Washington, D.C. 20231.

Cederic Rodgers



Name of Person Mailing Application

Signature of Person Mailing Application

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

TBK-102-US

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

U.S. APPLICATION NO. (if known, see 37 CFR 1.5)

INTERNATIONAL APPLICATION NO.
PCT/US98/11312INTERNATIONAL FILING DATE
05 JUN 1998PRIORITY DATE CLAIMED
06 JUN 1997

TITLE OF INVENTION
COMPOUNDS, COMPOSITIONS AND METHOD SUITABLE FOR AMELIORATION OF WITHDRAWAL SYNDROMES
AND WITHDRAWAL-INDUCED BRAIN DAMAGE

APPLICANT(S) FOR DO/EO/US
TABAKOFF, Boris; SNELL, Lawrence; and HOFFMAN, Paula L.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. (X) This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. () This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. (X) This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. () A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. (X) A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. () is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. () has been transmitted by the International Bureau.
 - c. (X) is not required, as the application was filed in the United States Receiving Office (RO/US).
6. () A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. (X) Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. () are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. () have been transmitted by the International Bureau.
 - c. (X) have not been made; however, the time limit for making such amendments has NOT expired.
 - d. () have not been made and will not be made.
8. () A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. (X) An oath or declaration of the inventor(s) 35 U.S.C. 371(c)(4)) and **Power of Attorney** (Executed).
10. () A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern other document(s) or information included:

11. () An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. () An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. () A FIRST preliminary amendment.
- () A SECOND or SUBSEQUENT preliminary amendment.

US APPLICATION NO. (if known, see 37 CFR 1.5)	INTERNATIONAL APPLICATION NO. PCT/US98/11312	ATTORNEYS DOCKET NUMBER TBK-102-US
---	---	---------------------------------------

14. () A substitute specification.

15. () A change of power of attorney and/or address letter.

16. (X) Other items or information:

(X) A copy of Form PCT/DO/EO/901(a)(US VERSION);

(X) Small entity statement (unexecuted);

(X) Copy of International Search Report;

(X) Letter;

(X) Copy of U.S. Patent No. 5, 783,700.

<p>17. (X) The following fees are submitted:</p> <p>BASIC NATIONAL FEE (37 CFR 1.492(A)(1)-(5)):</p> <p>Search Report has been prepared by the EPO or JPO \$ 930.00</p> <p>International preliminary examination fee paid to USPTO (37 CFR 1.482) \$ 720.00</p> <p>No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) . \$ 790.00</p> <p>Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$ 1,070.00</p> <p>International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) \$ 98.00</p> <p style="text-align: center;">ENTER APPROPRIATE BASIC FEE AMOUNT =</p> <p>Surcharge of \$130.00 for furnishing the oath or declaration later than () 20 () 30 months from the earliest claimed priority date (37 CFR 1.492(e)).</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 15%;">Claims</th> <th style="width: 15%;">Number Filed</th> <th style="width: 15%;">Number Extra</th> <th style="width: 15%;">Rate</th> <th style="width: 15%;"></th> <th style="width: 15%;"></th> </tr> <tr> <td>Total Claims</td> <td style="text-align: center;">23</td> <td style="text-align: center;">3</td> <td style="text-align: center;">X \$ 22.00</td> <td style="text-align: center;">\$66.00</td> <td></td> </tr> <tr> <td>Independent Claims</td> <td style="text-align: center;">3</td> <td style="text-align: center;">0</td> <td style="text-align: center;">X \$ 82.00</td> <td style="text-align: center;">\$0.00</td> <td></td> </tr> <tr> <td colspan="3">MULTIPLE DEPENDENT CLAIM(S) (if applicable)</td> <td style="text-align: center;">+ \$270.00</td> <td></td> <td></td> </tr> <tr> <td colspan="4" style="text-align: right;">TOTAL OF ABOVE CALCULATIONS =</td> <td style="text-align: center;">\$856.00</td> <td></td> </tr> <tr> <td colspan="4">Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).</td> <td style="text-align: center;">\$428.00</td> <td></td> </tr> <tr> <td colspan="4" style="text-align: right;">SUBTOTAL =</td> <td style="text-align: center;">\$428.00</td> <td></td> </tr> <tr> <td colspan="4">Processing fee of \$130.00 for furnishing the English translation later than () 20 () 30 months from the earliest claimed priority date (37 CFR 1.492(f)).</td> <td style="text-align: center;">+</td> <td></td> </tr> <tr> <td colspan="4" style="text-align: right;">TOTAL NATIONAL FEE =</td> <td style="text-align: center;">\$428.00</td> <td></td> </tr> <tr> <td colspan="4">Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) and recordal fee (\$40)</td> <td></td> <td></td> </tr> <tr> <td colspan="4" style="text-align: right;">TOTAL FEES ENCLOSED =</td> <td style="text-align: center;">\$428.00</td> <td></td> </tr> <tr> <td colspan="4" rowspan="2"></td> <td style="text-align: center;">Amount to be Refunded</td> <td style="text-align: center;">\$</td> </tr> <tr> <td style="text-align: center;">Charged</td> <td style="text-align: center;">\$</td> </tr> </table>	Claims	Number Filed	Number Extra	Rate			Total Claims	23	3	X \$ 22.00	\$66.00		Independent Claims	3	0	X \$ 82.00	\$0.00		MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$270.00			TOTAL OF ABOVE CALCULATIONS =				\$856.00		Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).				\$428.00		SUBTOTAL =				\$428.00		Processing fee of \$130.00 for furnishing the English translation later than () 20 () 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				+		TOTAL NATIONAL FEE =				\$428.00		Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) and recordal fee (\$40)						TOTAL FEES ENCLOSED =				\$428.00						Amount to be Refunded	\$	Charged	\$	<p>CALCULATIONS PTO USE ONLY</p>
Claims	Number Filed	Number Extra	Rate																																																																								
Total Claims	23	3	X \$ 22.00	\$66.00																																																																							
Independent Claims	3	0	X \$ 82.00	\$0.00																																																																							
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$270.00																																																																								
TOTAL OF ABOVE CALCULATIONS =				\$856.00																																																																							
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).				\$428.00																																																																							
SUBTOTAL =				\$428.00																																																																							
Processing fee of \$130.00 for furnishing the English translation later than () 20 () 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				+																																																																							
TOTAL NATIONAL FEE =				\$428.00																																																																							
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) and recordal fee (\$40)																																																																											
TOTAL FEES ENCLOSED =				\$428.00																																																																							
				Amount to be Refunded	\$																																																																						
				Charged	\$																																																																						


- a. (X) A check in the amount of \$428.00 to cover the above fees is enclosed.
- b. () Please charge my Deposit Account No. _____ in the amount of _____ to cover the above fees. A duplicate copy of this sheet is enclosed.
- c. (X) The Commissioner is hereby authorized to charge any additional filing fees which may be required, or credit any overpayment to Deposit Account No. 15-0508. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

OLSON & HIERL, LTD.
20 North Wacker Drive
36th Floor
Chicago, Illinois 60606

Telephone: (312) 580-1180
Customer No.: 002387


SIGNATURE

Talivaldis Cepuritis
NAME

20,818
REGISTRATION NO.

- 1 -

**COMPOUNDS, COMPOSITIONS AND METHOD SUITABLE FOR
AMELIORATION OF WITHDRAWAL SYNDROMES AND
WITHDRAWAL-INDUCED BRAIN DAMAGE**

5 Cross-Referenced to Related Application

 This application claims the benefit of the filing date of U.S.
Provisional Application, Serial No. 60/048,848, filed on June 6, 1997.

Field of the Invention

10 This invention relates to compounds, compositions and methods
suitable for ameliorating withdrawal syndromes. More particularly, this invention
relates to amelioration of alcohol withdrawal, drug withdrawal and
withdrawal-induced brain damage.

15 Background of the Invention

 Pharmacological science has maintained that there exists a
structure-activity relationship in which the chemical structure of a compound of
interest (drug) determines the pharmacological selectivity and potency of the drug
See, for example, Ross E., chapter on "PHARMACODYNAMICS: MECHANISMS OF
20 DRUG ACTION AND THE RELATIONSHIP BETWEEN DRUG CONCENTRATION AND
EFFECT," in Hardman J.D., et al., eds., *Goodman and Gilman's The
Pharmacological Basis of Therapeutics*, 9th edition, pp. 29-41, McGraw-Hill,
New York (1990), (hereinafter "*Goodman and Gilman's* 9th Edition"). In many
instances, structural entities (pharmacophores) have been identified within the
25 overall chemical structure of a drug, which are critical for the drug's specificity
of action.

 For example, when one examines the structure of several
anticonvulsant agents such as diphenylhydantoin, phenobarbital, and
carbamazepine, which have all been shown to inhibit the action of voltage-
30 sensitive sodium channels in a use-dependent manner, (McNamara J.O., chapter
on "DRUGS EFFECTIVE IN THE THERAPY OF THE EPILEPSIES," in *Goodman and
Gilman's*, 9th edition), one notes that these compounds all contain a
diphenylureido group (or a group that can resemble a diphenylureido group in

- 2 -

three dimensional space) as part of their overall structure. The structural characteristics of compounds acting at the strychnine insensitive glycine site of the N-methyl-D-aspartate (NMDA) subtype of the glutamate receptor have also been examined and kynurenic acid derivatives have been defined as exemplary structures which can act as glycine antagonists at this site and inhibit the function of the NMDA receptor-gated ion channels (Leeson P.D., *et al.*, "THE GLYCINE SITE ON THE NMDA RECEPTOR: STRUCTURE-ACTIVITY RELATIONSHIPS AND THERAPEUTIC POTENTIAL," *J. Med. Chem.*, 37 4053-4067 (1994).

Both the overactivity of voltage-sensitive sodium channels and NMDA receptor-gated ion channels has been implicated in CNS hyperexcitability states that arise from a diverse etiology ranging from epilepsy (McNamara J.O., chapter on "DRUGS EFFECTIVE IN THE THERAPY OF THE EPILEPSIES," *Goodman and Gilman's*, 9th edition, pp. 461-486; MacDonald R.L. *et al.*, chapter on "GENERAL PRINCIPLES: PRINCIPLES OF ANTIEPILEPTIC DRUG ACTION," in Levy R., *et al.*, *Antiepileptic Drugs*, 3rd edition, Raven Press, New York (1989), to ethanol withdrawal. Thus, a chemical compound containing both the pharmacophore which is considered important for inhibiting voltage-sensitive sodium channels and a pharmacophore effective in inhibiting the NMDA receptor-gated ion channels, and having the duality of action particularly important for controlling central nervous system (CNS) hyperexcitability arising from ethanol withdrawal, other drug withdrawal, and other pathological conditions would be highly desirable.

Ethanol belongs to a class of pharmacologic agents that also includes other sedatives and hypnotics, such as barbiturates and benzodiazepines. The chronic and excessive ingestion or administration of ethanol (beverage alcohol), other agents with a similar pharmacologic profile (*e.g.*, benzodiazepines and barbiturates), and analgesics (opiates) produces significant changes in CNS function in human beings and other animals. These neuroadaptive changes in CNS function in response to the depressant actions of ethanol and other similar drugs or analgesic actions of opiates result from modification of the normal chemical communication within specific pathways which mediate information flow through assemblages of brain neurons. These significant changes in CNS

- 3 -

function, in general, result in a withdrawal syndrome which includes signs of CNS hyperexcitability when the chronic ingestion or administration of ethanol, other CNS depressant drugs, or opiates is abruptly terminated.

The withdrawal syndrome includes such manifestations of CNS hyperexcitability as tremors, insomnia, anorexia, seizures, convulsions, etc. The presence of a withdrawal syndrome related to the termination of administration of ethanol or other drug, e.g., barbiturate, or morphine is prima facie evidence that the individual is physically dependent on the drug being chronically ingested/administered. See, generally, Tabakoff, B. *et al.*, "BIOLOGY OF TOLERANCE AND DEPENDENCE," in Tabakoff, B., *et al.*, eds. Medical and Social Aspects of Alcohol Abuse, pp. 187-220, Plenum Press, New York (1983); and Jaffe, J.H., chapter on "DRUG ADDICTION AND DRUG ABUSE," in Gilman, A.G., *et al.*, eds., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th edition, pp. 522-573, Pergamon Press, New York (1990) (hereinafter "Goodman and Gilman's, 8th Edition"). Also, Edwards, G. "THE ALCOHOL DEPENDENCE SYNDROME: A CONCEPT AS STIMULUS TO ENQUIRY," British Journal of Addiction, 81 171-183, 1986; Wikler, G., "DYNAMICS OF DRUG DEPENDENCE: IMPLICATIONS OF A CONDITIONING THEORY FOR RESEARCH AND TREATMENT," Arch. Gen. Psychiatry, 28 611-616 (1973) and others have written extensively that avoidance of signs and symptoms of ethanol and other drug withdrawal are the impetus for further drug-taking behavior, and relapse occurs, in part, as an attempt at self-medicating withdrawal signs. One can thus contemplate that an efficacious medication for treatment of addictive drug withdrawal would also be efficacious in promoting the termination of drug-taking behavior and preventing relapse in those individuals who stop ingesting alcohol or other drugs. There is currently no single class of compounds suitable for the treatment of drug withdrawal syndromes because the current therapies are with medications which have cross-dependence potential (e.g., benzodiazepines and methadone) or treat only a limited portion of the withdrawal syndrome (e.g., propranolol for ethanol withdrawal).

Current therapies include: (a) transfer to less efficacious compounds (e.g., methadone) for opiate withdrawal; (b) treatment with

- 4 -

sympatholytics (e.g., the β -adrenergic receptor antagonist propranolol or the α_2 -adrenergic receptor agonist clonidine) for opiate or ethanol withdrawal; and (c) treatment with anxiolytics, neuroleptics or sedatives (e.g., benzodiazepines or barbiturates) for ethanol withdrawal.

5 Research has demonstrated that the signs and symptoms of ethanol, barbiturate, and opiate withdrawal syndromes are quite similar in humans and lower animal species. Because of this similarity, the underlying neurochemical mechanisms of the human manifestations of ethanol, barbiturate, and opiate physical dependence and drug withdrawal can be predictively studied in
10 non-human mammalian animal species.

 Studies have demonstrated that the chronic treatment of mice with ethanol or barbiturates results in the up-regulation of the function of the brain excitatory neurotransmitter systems (i.e., the neuronal systems which use glutamate as a neurotransmitter substance). See, for example, Grant, K.A., *et al.*, "ETHANOL WITHDRAWAL SEIZURES AND THE NMDA RECEPTOR COMPLEX," Eur. J. Pharmacol., 176 289-296 (1990); Rabbani, M. *et al.*, "POSSIBLE INVOLVEMENT OF NMDA RECEPTOR-MEDIATED TRANSMISSION IN BARBITURATE PHYSICAL DEPENDENCE," Brit. J. Pharmacol., 111 89-96, (1994). In particular, chronic exposure to ethanol or barbiturates results in an increased number of the
15 receptors for glutamate known as the N-methyl-D-aspartate (NMDA) receptors. Similarly, the development of tolerance to and physical dependence on opiates has been shown to involve NMDA receptors. See, Elliott, K., *et al.*, "N-METHYL-D-ASPARTATE (NMDA) RECEPTORS, MU AND KAPPA OPIOID TOLERANCE, AND PERSPECTIVES ON NEW ANALGESIC DRUG DEVELOPMENT,"
20 Neuropsychopharmacol., 13 347-356 (1995).

 The increase in NMDA receptor function has been linked at the molecular and cellular level with the generation of the characteristic signs of CNS hyperexcitability during withdrawal from drugs such as ethanol, barbiturates, or opiates. A number of compounds which are inhibitors of NMDA receptor
30 function have been proposed and tested as treatments for the ethanol withdrawal syndrome. However, such medications, particularly agents acting as blockers of the NMDA receptor ion channel and those competing with glutamate at the

- 5 -

glutamate binding site, have a significant drawback, since such NMDA receptor antagonists themselves interfere with cognitive function. See Collingridge, G.L., *et al.*, "EXCITATORY AMINO ACID RECEPTORS IN THE VERTEBRATE CENTRAL NERVOUS SYSTEM," *Pharmacol. Rev.*, 40 143-210 (1989). Recent work has also suggested that the non-competitive NMDA receptor antagonist, dizocilpine maleate (MK-801), reduces the development of morphine tolerance as well as the effects of withdrawal (Trujillo, K.A. *et al.*, "EXCITATORY AMINO ACIDS AND DRUGS OF ABUSE: A ROLE FOR N-METHYL-D-ASPARTATE RECEPTORS IN DRUG TOLERANCE, SENSITIZATION AND PHYSICAL DEPENDENCE," *Drug Alcohol Depend.*, 38 139-154 (1995)), but only at doses which are known to induce marked behavioral stimulation and ataxia.

The NMDA receptor glycine site antagonists have been introduced to overcome some of the negative effects of the other NMDA receptor antagonists. See Leeson, P.D., *et al.*, "THE GLYCINE SITE ON THE NMDA RECEPTOR: STRUCTURE-ACTIVITY RELATIONSHIPS AND THERAPEUTIC POTENTIAL," *J. Med. Chem.*, 37 4053-4067 (1994). Such agents do possess some anticonvulsant activity (Rowley, M., *et al.*, "3-ACYL-4 HYDROXYQUINOLINE-2(1H)-ONES. SYSTEMICALLY ACTIVE ANTICONVULSANTS ACTING BY ANTAGONISM AT THE GLYCINE SITE OF THE N-METHYL-D-ASPARTATE RECEPTOR COMPLEX," *J. Med. Chem.*, 36 3386-3396 (1993)), but the prototypical members of this class of agents, the R-(+) isomer of 3-amino-1-hydroxypyrrolidin-2-one, (\pm)HA-966, and 7-chlorokynurenate, have demonstrated a relative ineffectiveness at reducing or preventing the signs and symptoms of opiate withdrawal (Kosten, T.A., *et al.*, "THE SEVERITY OF NALOXONE-PRECIPITATED OPIATE WITHDRAWAL IS ATTENUATED BY FELBAMATE, A POSSIBLE GLYCINE ANTAGONIST," *Neuropsychopharmacology*, 13 323-333 (1995)) and ethanol withdrawal.

In generalized neuroexcitability disorders, that include drug withdrawal and some forms of epilepsy, two distinct phenomena important to the generation of seizures can be distinguished, i.e., initiation (development of seizure focus) and propagation (spread of seizure to contiguous and distant anatomical sites. See Rall, T.W., *et al.*, chapter on "DRUGS EFFECTIVE IN THE

- 6 -

THERAPY OF THE EPILEPSIES" in Goodman and Gilman's, 8th edition, pp. 436-462. Blockade of generalized seizure initiation is amenable to therapeutic strategies employing NMDA receptor antagonists (Croucher, M.J., *et al.*, "7-CHLOROKYNURENIC ACID, A STRYCHNINE-INSENSITIVE GLYCINE RECEPTOR ANTAGONIST, INHIBITS LIMBIC SEIZURE KINDLING," Neurosci. Lett., 118 29-32 (1990)). Agents which block propagation of neuroexcitability by blocking, in a use-dependent manner, voltage-sensitive sodium channels, have been used to block propagation and control epilepsy-related generalized seizures. These compounds have low levels of sedation, but the aura associated with initiation events is not controlled by such agents.

Carbamazepine is prototypic of the general class of voltage-sensitive sodium channel blockers and although it has been employed to treat ethanol withdrawal in humans, its effectiveness is equivocal (Erstad, B.L., *et al.*, "MANAGEMENT OF ETHANOL WITHDRAWAL," Am. J. Health-Syst. Pharm., 52 697-709 (1995)). Animal studies show that carbamazepine is not effective in reducing, by itself, the signs and symptoms of ethanol withdrawal (Grant K. *et al.*, "COMPARISON OF THE EFFECTS OF THE UNCOMPETITIVE N-METHYL-D-ASPARTATE ANTAGONIST (\pm)-5-AMINOCARBONYL-10,11-DIHYDRO-5H-DIBENZO[A,D]CYCLOHEPTEN-5,10-IMINE (ADCI) WITH ITS STRUCTURAL ANALOGS DIZOCILPINE (MK-801) AND CARBAMAZEPINE ON ETHANOL WITHDRAWAL SEIZURES," J. Pharmacol. Exp. Ther., 260 1017-1022 (1992)).

Physical dependence on ethanol and other sedatives or hypnotics can generate deleterious effects on the CNS in addition to generating signs of withdrawal. A significant portion of the brain damage evident in alcoholics is likely to be the cumulative result of multiple withdrawal episodes during the lifetime of these individuals. The deleterious effect of ethanol withdrawal on brain morphology has been demonstrated. See, for example, Brandao, F., *et al.*, "PIRACETAM IMPEDES HIPPOCAMPAL NEURONAL LOSS DURING WITHDRAWAL AFTER CHRONIC ETHANOL INTAKE," Alcohol, 12 279-288 (1995); and Daryanani, H.E., *et al.*, "ALCOHOLIC WITHDRAWAL SYNDROME AND SEIZURES," Alcohol & Alcoholism, 29 323-328 (1994).

- 7 -

The deleterious effects of ethanol dependence and withdrawal have also been demonstrated in in vitro studies in which neurons exposed chronically to ethanol in culture are more susceptible to excitotoxic effects of glutamate, following ethanol withdrawal. See, for example, Iorio, K.R., *et al.*,

- 5 "GLUTAMATE-INDUCED NEUROTOXICITY IS INCREASED IN CEREBELLAR GRANULE CELLS EXPOSED CHRONICALLY TO ETHANOL," *Eur. J. Pharmacol.*, 248 209-212 (1993); Ahern, K.B., *et al.*, "ENHANCEMENT OF NMDA TOXICITY AND CALCIUM RESPONSES BY CHRONIC EXPOSURE OF CULTURED CORTICAL NEURONS TO ETHANOL," *Neurosci. Lett.*, 165 211-214 (1994); and Chandler,
10 L.J., *et al.*, "CHRONIC ETHANOL EXPOSURE POTENTIATES NMDA EXCITOTOXICITY IN CEREBRAL CORTICAL NEURONS," *J. Neurochem.*, 60 1578-1581 (1993).

- The increased excitotoxicity in the ethanol-withdrawn cells has also been explained by the up-regulation of the number of NMDA receptors caused by
15 chronic exposure of the neurons to ethanol. Thus, there is a need for medications to treat dependence on or prevent the withdrawal syndrome from ethanol (or barbiturate) usage that beneficially ameliorate ethanol withdrawal-induced neuronal damage.

- Since the pharmacological specificity of a chemical compound is
20 determined by structural entities (pharmacophores) which are part of the overall structure of the pharmacologically active agent, an ideal compound would combine two or more pharmacophores with specific pharmacological properties to embody the pharmacological properties of both pharmacophores. In particular, a compound designed to possess, in one molecule, properties to both block voltage-
25 sensitive sodium channels and to antagonize the glycine site of the NMDA receptor would be of far greater utility in controlling drug withdrawal CNS hyperexcitability than agents currently available. This invention provides a series of novel compounds that embody such pharmacological properties.

30 Summary of the Invention


Compounds, compositions and a method suitable for treating withdrawal syndromes, particularly arising from alcohol or drug dependence and

- 8 -

withdrawal or withdrawal-induced brain damage manifested in a patient suffering withdrawal symptoms is disclosed. The term "withdrawal syndromes" as used herein includes, but is not limited to, manifestations of one or more symptoms of CNS hyperexcitability associated with alcohol withdrawal syndromes,

- 5 neuroexcitability disorders associated with drug withdrawal syndromes, neural brain damage induced by alcohol or drug dependence withdrawal and like neurodegenerative disorders associated with chronic drug use and withdrawal.

A preferred method comprises administering a physiologically effective amount of a compound having the general formula (I):



10

a tautomer thereof, a pharmacologically acceptable ester, amide, salt, ether, or an acid addition salt thereof;

wherein R¹ represents hydrogen or an alkyl group of 1 to 6 carbon atoms;

15

R² and R³ each independently represent phenyl which may be unsubstituted or substituted one or more times with substituents selected from the group consisting of alkoxy, cycloalkoxy, alkyl, and cycloalkyl groups containing up to 6 carbon atoms, hydrogen, hydrocarbon selected from the group consisting of straight chain, branched, cyclic, and heterocyclic groups containing up to 18

20

carbon atoms, halogen, cyano, trifluoromethyl, nitro, -OR^a, -SR^a, -NR^aR^b, NR^aCOR^b, -NR^aCO₂R^b, -NR^aSO₂R^b, -NRⁱCZNR^aR^b, -CO₂, or -CONR^aR^b; wherein R^a, R^b, Rⁱ each independently represent hydrogen or hydrocarbon as described above and can be the same or different and Z represents oxygen,

- 9 -

sulphur, or a group of formula =N,E; wherein E represents hydrocarbon as described above or an electron-withdrawing group; or

R² and R³ together with the intervening carbon atom represent carbonyl (C=O), thiocarbonyl (C=S), imino (C=N,R^a), oximino (C=N,OR^a),
5 or a 3- to 8-membered ring containing from zero to 4 hetero-atoms selected from the group consisting of oxygen, nitrogen, sulphur and phosphorus; wherein R^a represents hydrogen or hydrocarbon as described above;

wherein each of the R² and R³ substituents can be the same or different; and

10 X represents halogen and each of the 5, 7, substituents can be the same or different.

Administration of the compound can be by oral, intravenous, subcutaneous, intramuscular, intraperitoneal, transdermal or buccal means for therapeutic treatment.

15 Preferred compounds of the general formula (I) are N-substituted 4-ureido-5,7-dihalo-2-carboxy quinoline compounds. Particularly preferred compounds were derivatives of kynurenic acid, hereafter referred to generally as DCUK compounds. Presently preferred DCUK compounds are (N,N-diphenyl)-4-ureido-5,7-dichloro-2-carboxy-quinoline (DCUKA); (N,N-diphenyl)-4-ureido-
20 5,7-dichloro-2-carboxy-quinoline methyl ester)(DCUK-OMe); and N-phenyl, N-[2-methoxy]phenyl)-4-ureido-5,7-dichloro-2-carboxy-quinoline (MeO-DCUKA) which demonstrate affinity for both the strychnine-insensitive glycine binding site on the NMDA receptor complex and voltage-sensitive sodium channels.

The inventive DCUK compounds beneficially possess activity in
25 reducing drug withdrawal-induced and excitotoxin-induced CNS hyperexcitability and neuronal damage at doses devoid of CNS depressant effects. Even at high doses, the DCUK compounds efficiently inhibit, in a use dependent manner, voltage sensitive sodium channels and inhibit NMDA receptor function without inducing the adverse marked behavioral stimulation and ataxia effects associated
30 with known NMDA receptor antagonists or voltage sensitive sodium channel blockers. Additionally, the inventive DCUK compounds beneficially reduce or prevent in vitro measures of glutamate excitotoxicity.

Brief Description of the Drawings

In the drawings,

FIG. 1 shows the effects of DCUK compounds on the binding of
[³H]5,7-dichlorokynurenate ([³H]5,7-DCKA) to rat cortical membranes (1A) and
5 the binding of [³H]batrachotoxinin ([³H]BTX) to rat cortical synaptosomes (1B);

FIG. 2 shows the effects of DCUKA and DCUK-OMe on the
binding of [³H]dizocilpine to rat cortical membranes;

FIG. 3 shows the inhibitory effect of DCUKA on NMDA-induced
currents in oocytes expressing recombinant NMDA receptors (3A) and the effects
10 of increasing concentrations of glycine in reversing DCUKA actions (3B-1).

FIG. 4 shows the effect of DCUKA on sodium currents obtained
from CHO cells stably expressing VSNaCs.

FIG. 5 shows the lack of effects of (±)HA-966 (5A) and 7-Cl
kynurenic acid (5B) on ethanol withdrawal-induced seizures in C57BL/6 mice;

15 FIG. 6 shows the protective effects of DCUK-OMe on ethanol
withdrawal-induced seizures in C57BL/6 mice;

FIG. 7 shows the anxiolytic effects of DCUK-OMe in mice, as
measured by use of the elevated plus-maze apparatus.

FIG. 8 shows the anticonvulsant effects of DCUK-OMe, as
20 measured by suppression of audiogenic seizures in DBA/2J mice.

FIG. 9 shows the protective effects of DCUK-OMe on
glutamate-induced excitotoxic cell death in primary cultures of rat cerebellar
granule cells;

FIG. 10 shows the protective effects of MeO-DCUKA on kainate-
25 induced increases in heat shock protein (HSP72) in the hippocampus of C57BL/6
mice;

FIG. 11 shows the incoordinating effects of carbamazepine and
diazepam on rotarod performance in naive Swiss-Webster mice and lack of
incoordinating effects with DCUK-OMe.

30 FIG. 12 shows the significant potentiation of the sedative/anesthetic
effects of ethanol by diazepam and no significant potentiation of ethanol's actions
by DCUK-OMe.

- 11 -


Fig. 13 shows the effects of (\pm)HA-966 on rotarod performance in naive C57BL/6 mice.

Detailed Description of Preferred Embodiment

- 5 Disclosed are compounds, compositions and a method suitable for treating dependence on, or preventing the withdrawal syndrome from being manifested during withdrawal from, the chronic use of ethanol, or other sedative or hypnotic or analgesic drugs in a patient (humans or other mammalian animal species). Withdrawal syndrome manifestations include, but are not limited to
- 10 CNS hyperexcitability, such as tremors, insomnia, anorexia, disorientation, seizures, convulsions, anxiety or the like. The present compounds, compositions and method also provide for treating neurodegenerative disorders associated with chronic drug use and withdrawal induced brain damage.

- The method provided by the present invention comprises
- 15 administering by systemic means to a patient in need of such treatment or prevention an effective ameliorating amount of a compound which exhibits both an affinity for the strychnine-insensitive glycine binding site on the NMDA receptor complex and affinity for voltage-sensitive sodium channels (VSNaC).

A preferred compound embodiment has the general formula (I):



20

a tautomer thereof, a pharmacologically acceptable ester, amide, salt, ether, or an acid addition salt thereof;

- 12 -

wherein R^1 represents hydrogen or an alkyl group of 1 to 6 carbon atoms;

R^2 and R^3 each independently represent phenyl which may be unsubstituted or substituted one or more times with substituents selected from the group consisting of alkoxy, cycloalkoxy, alkyl, and cycloalkyl groups containing up to 6 carbon atoms, hydrogen, hydrocarbon selected from the group consisting of straight chain, branched, cyclic, and heterocyclic groups containing up to 18 carbon atoms, halogen, cyano, trifluoromethyl, nitro, $-OR^a$, $-SR^a$, $-NR^aR^b$, NR^aCOR^b , $-NR^aCO_2R^b$, $-NR^aSO_2R^b$, $-NR^iCZNR^aR^b$, $-CO_2$, or $-CONR^aR^b$;
 10 wherein R^a , R^b , R^i each independently represent hydrogen or hydrocarbon as described above and can be the same or different and Z represents oxygen, sulphur, or a group of formula $=N,E$; wherein E represents hydrocarbon as described above or an electron-withdrawing group; or

R^2 and R^3 together with the intervening carbon atom represent
 15 carbonyl ($C=O$), thiocarbonyl ($C=S$), imino ($C=N,R^a$), oximino ($C=N,OR^a$), or a 3- to 8-membered ring containing from zero to 4 hetero-atoms selected from the group consisting of oxygen, nitrogen, sulphur and phosphorus; wherein R^a represents hydrogen or hydrocarbon as described above;

wherein each of the R^2 and R^3 substituents can be the same or
 20 different; and

X represents halogen and each of the 5, 7, substituents can be the same or different.

The term "alkyl" as used herein refers to lower alkyl groups containing less than 7 carbon atoms. A preferred alkyl group has 1 to 3 carbon atoms. The term "hydrocarbon" as used herein includes straight-chained,
 25 branched, and cyclic groups, including heterocyclic groups, containing up to 18 carbon atoms, suitably up to 15 carbon atoms, and conveniently up to 12 carbon atoms. The term "halogen" as used herein includes chloro, fluoro, bromo and iodo substituents, preferably chloro. The term "alkoxy" as used herein refers to
 30 alkoxy groups containing less than 7 carbon atoms, preferably 1 to 3 carbon atoms. The term "substituted phenyl" refers to phenyl having one or more substituents selected from the group consisting of alkoxy, cycloalkoxy, alkyl, and

- 13 -

cycloalkyl groups containing up to 6 carbon atoms. A preferred phenyl has an alkoxy group substituent having 1 to 3 carbon atoms.

For convenience, N-substituted-4-ureido-5,7-dihalo-2-carboxy quinolines of formula (I) will be referred to herein simply as the compounds of formula I. In one presently preferred compound of formula (I), each of the X substituents is chloro, R¹ is hydrogen, and R² and R³ each is a phenyl group; in another preferred compound of formula (I), each of the X substituents is chloro, R¹ is an alkyl group having 1 to 3 carbon atoms, and R² and R³ each is a phenyl group. In yet another preferred compound of formula (I), each of the X substituents is chloro, R¹ is hydrogen, one of R² and R³ is an unsubstituted phenyl group and the other is phenyl having an alkoxy substituent having 1 to 3 carbon atoms. A particularly preferred compound of formula I is an N-substituted-4-ureido-5,7-dichloro-quinolinic acid.

The salts of the compounds of formula I preferably are non-toxic, pharmaceutically acceptable salts suitable for medical use. Other salts may, however, be useful in the preparation of the compounds according to the invention or in the preparation of their non-toxic pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts of the compounds of this invention include alkali metals salts, *e.g.*, sodium or potassium salts; alkaline earth metal salts, *e.g.*, calcium or magnesium salts; and salts formed with suitable organic ligands *e.g.*, quaternary ammonium salts. When appropriate, acid addition salts may, for example, be formed by mixing a solution of the compound prepared according to the invention with a solution of a pharmaceutically acceptable non-toxic acid such as hydrochloric acid, fumaric acid, maleic acid, succinic acid, acetic acid, citric acid, tartaric acid, carbonic acid, or phosphoric acid.

In a preferred method embodiment, the compounds of formula I are administered via a pharmaceutical formulation. Suitable formulations of the present invention comprise at least one compound of this invention present in a therapeutically or pharmaceutically effective dose level, optionally together with one or more pharmaceutically acceptable additional ingredients, such as sympatholytics, *e.g.*, the β -adrenergic receptor antagonist propranolol, or the

- 14 -

α_2 -adrenergic receptor agonist clonidine or anxiolytics such as benzodiazepines or barbiturates.

The invention also provides a method suitable for treating or preventing convulsions arising from conditions other than drug withdrawal, such as epilepsy, febrile seizures, poisoning by exogenous and endogenous excitatory neuroreceptor agonists, or inhibitory neuroreceptor antagonists and neurotoxins, including environmental neurotoxins. The method comprises administering to a patient in need of such treatment or prevention an effective amount of an antagonist compound exhibiting affinity for both the strychnine-insensitive glycine binding site on the NMDA receptor complex and affinity for voltage dependent sodium channels.

In addition, the present invention also provides a method suitable for treating or preventing neurodegenerative disorders arising from conditions, other than drug withdrawal, such as but not limited to stroke, hypoglycemia, cerebral palsy, transient cerebral ischemic attack, perinatal asphyxia, epilepsy, Huntington's chorea, Alzheimer's disease, Amyotrophic Lateral Sclerosis, Parkinson's disease, olivo-ponto-cerebellar atrophy, anoxia such as from drowning, spinal cord and head injury, and poisoning by exogenous and endogenous excitatory neuroreceptor agonists, or inhibitory neuroreceptor antagonists and neurotoxins, including environmental neurotoxins, comprising administering to a patient in need of such treatment or prevention an effective amount of an antagonist compound exhibiting affinity for both the strychnine-insensitive glycine binding site on the NMDA receptor complex and for voltage dependent sodium channels. Preferably the compound freely crosses the blood brain barrier. Preferably the compound of formula I is an N-substituted-4-ureido-5,7-dihalo-quinolinic acid, a tautomer, or pharmacologically acceptable ester, amide, salt, ether, and acid addition salt thereof.

The present invention is also useful as a method suitable for treating or preventing anxiety arising from conditions other than drug withdrawal, such as, but not limited to, panic disorder, phobias, obsessive-compulsive disorder, and personality disorder, comprising administering by systemic means

- 15 -

to a patient in need of such treatment or prevention an effective amount of an antagonist compound exhibiting affinity for both the strychnine-insensitive glycine binding site on the NMDA receptor complex and for voltage dependent sodium channels. Preferably the compound freely crosses the blood brain barrier. A
5 preferred compound embodiment is an N-substituted 4-ureido-5,7-dihalo-quinolinic acid of the formula I, a tautomer, or pharmacologically acceptable ester, amide, salt, ether, and acid addition salt thereof. More preferably, the compound of formula I is an N-substituted 4-ureido-5,7-dichloro-quinolinic acid.

Alternatively, the present invention may be suitably used as a
10 method of treating or preventing schizophrenia, comprising administering by systemic means to a patient in need of such treatment or prevention an effective amount of an antagonist compound exhibiting affinity for both the strychnine-insensitive glycine binding site on the NMDA receptor complex and for voltage dependent sodium channels. Preferably the compound freely crosses
15 the blood brain barrier. Preferably the compound of formula I is an N-substituted-4-ureido-5,7-dihalo-quinolinic acid, a tautomer, or pharmacologically acceptable ester, amide, salt, ether, and acid addition salt thereof.

The method and compositions of the present invention may also be
20 suitable for use for reducing or preventing the development of tolerance to opiates or other beneficial drugs. The method comprises administering by systemic means to a patient in need of such treatment or prevention an effective amount of an antagonist compound of formula I exhibiting affinity for both the strychnine-insensitive glycine binding site on the NMDA receptor complex and
25 for voltage dependent sodium channels. Preferably the compound freely crosses the blood brain barrier. More preferably the compound of formula I is an N-substituted-4-ureido-5,7-dihalo-quinolinic acid, a tautomer, or pharmacologically acceptable ester, amide, salt, ether, and acid addition salt thereof.

30 In a preferred method embodiment, the compounds of formula I may be administered concomitantly with or prior to administration of a

- 16 -

tolerance-producing but otherwise beneficial compound. In a composition embodiment, a composition may contain a tolerance producing compound and an effective amount of an antagonist compound of formula I exhibiting affinity for both the strychnine-insensitive glycine binding site on the NMDA receptor complex and for voltage dependent sodium channels as a combined preparation for simultaneous, separate or sequential use in the therapy of a disorder in which treatment with the tolerance-inducing compound is beneficial.

The disclosed compounds can be administered as part of a pharmaceutical composition comprising a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers include water, saline, buffers, and other compounds described, *e.g.*, in The Merck Index, Merck & Co., Rahway, N.J. and like references familiar to those skilled in the pharmaceutical arts. The inventive pharmaceutical composition can be administered by oral, intravenous, subcutaneous, intramuscular, intraperitoneal, transdermal or buccal means for therapeutic treatment. The pharmaceutical composition can be administered in a variety of unit dosage forms depending upon the method of administration. For example, unit dosage forms suitable for oral administration include powder, tablets, pills, capsules, solutions, suspensions, emulsions, caplets, dragees and the like.

Compositions for intravenous administration preferably comprise a solution of the compound dissolved or suspended in an acceptable carrier, preferably an aqueous carrier.


For solid dosage form compositions, conventional substantially non-toxic solid carriers can be used. Suitable carriers include, without limitation thereto, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like. For oral administration, a composition comprises at least one pharmaceutically acceptable excipient, such as those carriers previously listed, and about 0.1 weight percent to about 95 weight percent of the compound of formula I as active ingredient. Preferably the composition comprises about 20 weight percent active ingredient.

- 17 -

Compounds can be administered as a single daily dose or preferably divided doses on a daily basis, which will vary with the nature of the active ingredient. Doses of up to about 500 mg/kg of body weight may be administered. Preferably for a human patient, a dose in the range of about 10 to about 100 mg/kg of body weight may be administered from one to about 3 times per day or as necessary to prevent or ameliorate withdrawal symptoms.

One preferred compound embodiment, (N,N-diphenyl)-4-ureido-5,7-dichloro-2-carboxy-quinoline (DCUKA), was synthesized as a derivative of kynurenic acid in the synthesis phases I-V as explained and illustrated below, but is not limited thereto.

- 18 -



Synthesis Phase I

3,5 Dichloroaniline (1) (3.24g, 20 mmol) and dimethyl acetylenedicarboxylate (2) (2.46 ml, 2.84g, 20 mmol) were added under nitrogen with stirring to anhydrous methanol. The mixture was refluxed for 18 hours.

- 5 The solution was evaporated under reduced pressure to give a bright yellow solid. Recrystallization (twice) from methanol yielded the dimethyl anilinofumarate (3) as a yellow crystalline solid (1.6g). The absorption peak values (in ppm) found

- 19 -

in the ^1H NMR spectrum of the intermediate dimethyl anilino fumarate compound (3) were 3.8 (6H, 2 x s), 5.6 (1H, s), 6.8 (2H, s), 7.1 (1H, s), 9.6 (1H, broad s). The ^{13}C NMR spectrum values found were 51.5, 53.0, 97.1, 118.8, 123.9, 135.3, 142.3, 146.1, 164.0, 169.4.

5

Synthesis Phase II

The dimethyl anilino fumarate was cyclized as follows. Dimethyl anilino fumarate (3) (1g) was added portionwise, with vigorous stirring to diphenyl ether (20 ml) which was maintained within the range of about 240 to about 260°C (about 464 to 500°F) under nitrogen. The mixture was stirred at about 245°C (about 473°F) for an hour, then allowed to cool to room temperature (about 21-23°C). The suspension was diluted with hexanes, at which point the product precipitated. The mixture was filtered, and the filtrate washed thoroughly with hexanes. Recrystallization from ethanol gave the 4(1H)-quinolone-2-carboxylate compound (4) as a creamy white solid.

15

Synthesis Phase III

The 4(1H)-quinolone-2-carboxylate was aminated as follows. Chlorosulphonyl isocyanate (0.2 mmol, 28 mg, 17 μl) was added to a solution of the quinolone compound (4) (50 mg., 0.19 mmol) in dry acetonitrile (5 ml) at room temperature (about 21-23°C). The resulting mixture was heated to reflux for about 2 hours (until the evolution of carbon dioxide ceased). A solution of HCl in dry methanol was added, and the reaction mixture cooled to ambient room temperature. Evaporation and crystallization from methanol yielded the salt of the aminoquinoline. This salt compound was dissolved in water, neutralized with a sodium carbonate solution (8%), and extracted twice with ethyl acetate (25 ml each extract). The organic extracts were combined, dried over magnesium sulfate, filtered and evaporated to give the amino quinoline compound (5), which was purified by crystallization from methanol. The absorption peak values (in ppm) found in the ^1H NMR spectrum for the amino quinoline (5) compound were 4.2 (3H, s), 6.2 (1H, broad s.), 7.4 (1H, s), 7.45 (1H, s), 7.6 (1H, d, J=2.2Hz), 8.2 (1H, d, J=1.95Hz).

25

30

- 20 -

Synthesis Phase IV

The amino quinoline compound was acylated as follows. Freshly washed sodium hydride (NaH) was added portionwise to a stirred solution of the quinoline compound (5) (20 mg., 0.075 mmol) in dried tetrahydrofuran (THF) (2 ml) under nitrogen. The mixture was stirred at room temperature for about 30 minutes. Diphenyl carbamoyl chloride was then added, and the mixture was allowed to stir for about 24 hours with Thin Layer Chromatography (TLC) monitoring (1:1, ethyl acetate-hexanes). At this point the reaction was seen to be incomplete, as evidenced by a remainder of starting material. A further equivalent amount of the NaH and the carbamoyl chloride was added and the reaction was allowed to stir further for about 18 hours at ambient room temperature at which point no starting material remained. The mixture was evaporated under reduced pressure and flashed with 3:7 ethyl acetate-hexanes to give carbamoyl chloride and other co-products. Elution with 4:6 and then with 1:1 ethyl acetate-hexanes yielded the urea derivative, (N,N-diphenyl)-4-ureido-5,7-dichloro-2-carboxy methyl ester (6) compound (DCUK-OMe), as a white solid, which was recrystallized from diethyl ether (20 mg). The absorption peak values (in ppm) found in the ¹H NMR spectrum for the DCUK-OMe compound (6) were 4.1 (3H, s), 7.4-7.7 (m, 13H), 8.3 (1H, d, J=2.44Hz), 9.5 (1H, s), 9.6 (1H, broad s).


Synthesis Phase V

The DCUK-OMe compound was then hydrolyzed as follows. The DCUK-OMe compound (6) (3.5 mg) was dissolved in THF (5 ml) and lithium hydroxide (0.01 mmol, 0.24 mg) in water (100 μ l) was added, followed by water (2 ml). The mixture was stirred vigorously at ambient room temperature (about 21-23°C) with TLC monitoring (1:1 ethyl acetate-hexanes). After about 24 hours the ester (R_f 0.5) had disappeared in favor of another spot on the baseline. The THF was evaporated under reduced pressure and a further 20 ml of water was added to the remnants. Adjustment of the pH of the solution to a pH of 1 gave a white precipitate. The suspension was washed twice with ethyl acetate (20 ml). The combined organic extracts were washed with brine and dried over

- 21 -

magnesium sulfate. Filtration and evaporation yielded the final carboxylic acid, (N,N-diphenyl)-4-ureido-5,7-dichloro-2-carboxy-quinoline (DCUKA) compound (7), as a white solid which was recrystallized from diethyl ether. The absorption peak values (in ppm) in the ^1H NMR spectrum for the DCUKA compound (7) was 7.2-7.4 (H, m), 7.6 (1H, s), 8.0 (1H, s), 8.9 (1H, s), 9.1 (1H, s).

Alternatively, the DCUKA compound can be prepared as illustrated below.



The dichloroquinoline (represented by 4) may be synthesized as described by Heindel, N.D., *et al.*, "CYCLIZATION OF ANILINE-ACETYLENE

- 22 -

DICARBOXYLATE ADDUCTS: A MODIFIED CONRAD-LIMPACH METHOD FOR THE SYNTHESIS OF POTENTIAL ANTIMALARIALS," *J. Med. Chem.* 11 1218-1221 (1968). 3,5-Dichloroaniline, (1) a dihaloaniline, is refluxed with dimethyl acetylenedicarboxylate to produce substituted diester (3) in approximately 80% yield. Upon heating in diphenyl ether, the fumarate ester under goes cyclization to the quinoline carboxylate (4). The ester (4) can be readily aminated to the tosylamine (5) as described by Harrison, B.L., *et al.*, "4-
5 [(CARBOXYMETHYL)OXYL]- AND 4-[(CARBOXYMETHYL)AMINO]-5,7-DICHLOROQUINOLINE-2-CARBOXYLIC ACID: NEW ANTAGONISTS OF THE
10 STRYCHNINE-INSENSITIVE GLYCINE BINDING SITE ON THE N-METHYL-D-ASPARTATE RECEPTOR COMPLEX," *J. Med. Chem.* 33 3130-3132 (1990). The tosylamine (5) was acylated with diphenylcarbamoil chloride (6), followed by hydrolysis, to form the diphenyl urea derivative (7).

The following examples are for illustrative purposes only and are
15 not to be construed as limiting this invention in any manner.

EXAMPLE 1: Effect of DCUK compounds on the binding of
20 [³H]5, 7-DCKA to rat brain cortical membranes and [³H]BTX binding to rat brain cortical synaptosomes.

This example compares the effect of DCUK compounds on the binding of ligands defining the strychnine-insensitive glycine binding site on the NMDA receptor, and batrachotoxin binding to a site on voltage-sensitive sodium channels, to effects of the DCUK compounds on binding of ligands defining other
25 binding sites and receptors in rat brain cortical preparations.

Male Sprague-Dawley rats were killed, their brains removed, and their cerebral cortices dissected and binding of [³H]5,7-dichlorokynurenate ([³H]5,7-DCKA) assayed. [³H]5,7-DCKA binding assays were performed in crude synaptic membranes prepared by a modification of the method of Jones, *et al.*, *J. Pharmacol. Methods*, 21 161-168 (1989) the relevant disclosures of which
30 are incorporated herein by reference. The pelleted "buffy coat" fraction was obtained by centrifugation and frozen at about -80°C for at least 18 hours. On the day that the binding assays were performed, the pelleted membranes were

- 23 -

resuspended in 50 mM HEPES-KOH buffer (pH 7.8) containing 0.08% TRITON® X-100. After stirring for about 30 min at about 4°C, the membranes were pelleted by recentrifugation and then washed twice by resuspension in buffer and centrifugation.

5 [³H]5,7-DCKA binding assays were performed employing the well known procedure of Baron, B.M., *et al.*, a description of which can be found in "[³H]5,7-DICHLOROKYNURENIC ACID, A NOVEL RADIOLIGAND LABELS NMDA RECEPTOR-ASSOCIATED GLYCINE BINDING SITES," *Eur. J. Pharmacol. -Mol. Pharmacol. Sect.*, 206 149-154 (1991), the relevant disclosures of which are
10 incorporated herein by reference. Binding assays were performed in 0.5 ml volume using 150-200 µg of tissue, 20 nM [³H]5,7-DCKA and 3-300 µM DCUKA or MeO-DCUKA or 1-100 µM DCUK-OMe (all concentrations are final concentrations in 0.6% dimethyl sulfoxide (DMSO)). Incubations were performed for about 45 min at about 4°C followed by termination by
15 centrifugation. Bound radioactivity was quantitated by liquid scintillation spectroscopy. Non-specific binding was defined with 1 mM glycine.

The results obtained are plotted in FIG. 1A and are compared in Table 1A below to carbamazepine. From FIG. 1A and Table 1A, it is apparent that the DCUK compounds produced a concentration-dependent decrease in
20 [³H]5,7-DCKA binding suggesting that these compounds have affinity for the strychnine-insensitive glycine site on the NMDA receptor complex.

[³H]Batrachotoxinin ([³H]BTX) binding assays (defining binding to the voltage sensitive sodium channels) were performed in freshly prepared rat cortical crude synaptosomes according to the well-known method of Willow, M.,
25 *et al.* A description of the method can be found in Willow M., *et al.*, "INHIBITION OF BINDING OF [³H]BATRACHOTOXININ A 20-ALPHA-BENZOATE TO SODIUM CHANNELS BY THE ANTICONVULSANT DRUGS DIPHENYLHYDANTOIN AND CARBAMAZEPINE," *Mol. Pharmacol.*, 22 627-635 (1982), the relevant disclosures of which are incorporated herein by reference. The crude P₂
30 synaptosomal pellet was obtained by homogenization and centrifugation through 0.32 M sucrose-5 mM K₂HPO₄. The pellet was resuspended in sodium-free assay buffer containing (in mM) 50 HEPES, 5.4 KCl, 0.8 MgSO₄, 5.5 glucose, 130

- 24 -

choline chloride, (pH 7.6) containing 1 μ M tetrodotoxin and 1 μ g/ml scorpion venom. [3 H]BTX binding was performed in 1 ml using 300-400 μ g of tissue, 10 nM [3 H]BTX, and the same concentrations of the DCUK compounds as those used in the [3 H]5,7-DCKA binding assay. Incubations were performed for about 90 min at ambient room temperature (about 21-23°C) followed by vacuum filtration over GF/C filters. Bound radioactivity was quantitated by liquid scintillation spectroscopy. Non-specific binding was defined with 0.3 mM veratridine. The results obtained are plotted in FIG. 1B and are compared to carbamazepine below in Table 1A.

From FIG. 1B and Table 1A below, it is apparent that the DCUK compounds produced a concentration-dependent decrease in [3 H]BTX binding, suggesting that, in addition to their affinity at the glycine site of the NMDA receptor, these compounds also have significant affinity for voltage-sensitive sodium channels (VSNACs). In a separate test, KCl (135 mM) was substituted for choline chloride in the assay buffer in order to depolarize the synaptosomes. As can be seen in FIG. 1B and Table 1A, the affinity of MeO-DCUKA for the [3 H]BTX binding site was increased, suggesting that these compounds, like the prototypical sodium channel blocker, carbamazepine, exhibit a voltage-dependent block of VSNACs.

20

Table 1A

Compound	IC ₅₀ (μ M)	IC ₅₀ (μ M)
	[3 H]5,7-DCKA binding	[3 H]BTX binding
DCUK-OMe	5	25
MeO-DCUKA	35	64 (30)
Carbamazepine	none*	71 (56)
5,7-DCKA	0.11	none

25

- 25 -

Table 1B

DCUKA	
Ligand	IC ₅₀ (μM)
[³ H]5, 7-DCKA	22
[³ H]BTX	76
[³ H]CGP 39653	> 200
[³ H]kainate	> 200
[³ H]flunitrazepam	> 200
[³ H]rauwolscine	> 200
[³ H]ifenprodil	> 200

Notes to Tables 1A and 1B

[³H]5,7 dichlorokynurenate (5,7-DCKA), [³H]CGP 39653, [³H]kainate, [³H]ifenprodil, and [³H]flunitrazepam binding assays were performed in P₂-buffy coat membranes prepared from rat forebrain.

[³H]rauwolscine binding was performed in crude P₁ membranes.

[³H]Batrachotoxinin (BTX) binding was performed in synaptosomes prepared from rat forebrain. IC₅₀ values obtained under non-depolarizing or depolarizing conditions (135 mM KCl; values in parentheses).

none - no displacement at 100 μM.

none* - no displacement at 64 μM carbamazepine. Taken from McCabe, R.T., *et al.*, "Evidence for anticonvulsant and neuroprotectant action of felbamate medicated by strychnine-insensitive glycine receptors," *J. Pharmacol. Exp. Ther.*, 264 1248-1252, (1993).

In a separate study, 5-200 μM DCUKA was studied for its ability to displace [³H]CGP 39653, [³H]kainate, [³H]ifenprodil, and [³H]flunitrazepam binding. Rat cortical membranes, prepared as described for [³H]5,7-DCKA binding, were used to test whether the DCUK compounds have affinity for the glutamate site of the NMDA receptor, the polyamine binding site on the NMDA receptor, the kainate binding site on non-NMDA glutamate receptors, and the benzodiazepine binding site on the GABA_A receptor, respectively.

- 26 -

[³H]CGP 39653 binding assays were performed according to Sills, M., et al., a description of which can be found in *Eur. J. Pharmacol.*, **192** 19-24 (1991) the relevant disclosures of which are incorporated by reference, employing a 1.0 ml volume using 150-200 µg tissue, 2 nM [³H]CGP 39653, in 10 mM HEPES-KOH buffer (pH 7.6 at 4°C). Non-specific binding was defined with 0.1 mM L-glutamate. Incubations were for 60 min at 4°C, followed by filtration over GF/B filters.

[³H]Kainate binding assays were performed according to Braitman, D.J., et al., a description of which can be found in "INHIBITION OF [³H]KAINIC ACID RECEPTOR BINDING BY DIVALENT CATIONS CORRELATES WITH ION AFFINITY FOR THE CALCIUM CHANNEL," *Neuropharmacology*, **26** 1247-1251 (1987) the relevant disclosures of which are incorporated by reference, employing a 1.0 ml volume using 150-200 µg tissue, 1 nM [³H]kainate, in 50 mM HEPES-KOH buffer (pH 7.1 at 4°C). Non-specific binding was defined with 0.5 mM kainate. Incubations were for 60 min at 4°C, followed by centrifugation termination.

[³H]Flunitrazepam binding assays were performed according to Tehrani, M.H., et al., a description of which can be found in "AGE-RELATED LEVELS OF GABA/BENZODIAZEPINE BINDING SITES IN CEREBRUM OF F-344 RATS: EFFECTS OF EXERCISE," *Neurobiol. Aging*, **16** 199-204 (1995) the relevant disclosures of which are incorporated by reference, employing a 0.5 ml volume using 150-200 µg tissue, 1 nM [³H]flunitrazepam, 1 mM GABA, in 50 mM HEPES-KOH (pH 7.4 at 4°C). Non-specific binding was defined by 10 µM diazepam. Incubations were for 30 min at 4°C, followed by filtration over GF/C filters.

[³H]Ifenprodil binding assays were performed according to Shoemaker, H., et al., a description of which can be found in "BINDING OF [³H]IFENPRODIL, A NOVEL NMDA ANTAGONIST, TO A POLYAMINE-SENSITIVE SITE IN THE RAT CEREBRAL CORTEX," *Eur. J. Pharmacol.*, **176** 249-250 (1990), the relevant disclosures of which are incorporated by reference. The assay employed a 1.0 ml volume using 150-200 mg tissue, 2 nM [³H]ifenprodil, in a 50 mM HEPES-KOH (pH 7.4 at 4°C). Non-specific binding was defined with 10

- 27 -

μ M ifenprodil. Incubations were for 120 min at 4°C, followed by filtration over GF/B filters presoaked in 0.1% polyethyleneimine.

In addition, the ability of DCUKA to displace [3 H]rauwolscine binding was performed according to Broadhurst, *et al.*, a description of which can be found in "A REASSESSMENT OF THE BINDING OF [3 H]RAUWOLSCINE TO MEMBRANES FROM THE RAT CORTEX," *Neuropharmacology*, 25 287-295 (1986) the relevant disclosures of which are incorporated by reference, to test whether DCUK compounds have affinity for the α_2 -noradrenergic receptors. Rat cortices were homogenized in 20 volumes of ice-cold HEPES-KOH buffer (20 mM, pH 7.4) and twice centrifuged at 50,000 g for 20 min with an intermediate suspension in fresh buffer. The final pellet was stored at -20°C in 4 volumes of buffer. The binding of [3 H]rauwolscine was performed in a 0.5 ml volume using 250-300 μ g tissue and 1 nM [3 H]rauwolscine in 20 mM HEPES-KOH buffer (pH 7.4 at 23°C). Non-specific binding was defined by use of 100 μ M norepinephrine. Incubations were for 30 min at 23°C, followed by filtration over GF/B filters.

The results are shown in Table 1B. The data confirm that DCUKA, like DCUK-OMe and MeO-DCUKA, has affinity for both the strychnine-insensitive glycine site on the NMDA receptor complex and for the VSNaCs, but the DCUKA shows little affinity for receptors for other neurotransmitters or other ion channels.

EXAMPLE 2: Effect of DCUK compounds on the binding of [3 H]dizocilpine to rat cortical membranes.

In a further study, [3 H]dizocilpine binding was assayed in rat cortical membranes prepared as described for [3 H]5,7-DCKA binding in Example 1. [3 H]Dizocilpine (MK-801) binding assays were performed in a volume of 1 ml containing 100-150 μ g of tissue, 5 nM [3 H]dizocilpine, 10 μ M L-glutamate, 30 μ M MgSO_4 , and 100 or 300 μ M DCUKA or 30 or 100 μ M DCUK-OMe, in 10 mM HEPES-KOH buffer (pH 7.4 at 23°C). Incubations were for 30 minutes at room temperature. The reaction mixtures were filtered over GF/B filters presoaked in 0.1% polyethyleneimine. Bound radioactivity was quantitated by

- 28 -

liquid scintillation spectroscopy. Non-specific binding was defined with 20 μ M dizocilpine. Under these conditions, [3 H]dizocilpine binding can be used as a measure of the activation of the NMDA receptor ion channel by glycine. See, for example, Wong, E.H.F., *et al.*, "GLYCINE MODULATES [3 H]MK-801 BINDING TO THE NMDA RECEPTOR IN RAT BRAIN." *Eur. J. Pharmacol.*, 142 487-488 (1987).

The results obtained are plotted in FIG. 2 where open bars indicate no glycine added and hatched bars indicate 1 μ M glycine added to the incubation. Data were statistically analyzed by 2-way analysis of variance (ANOVA) followed by Tukey test. In FIG. 2, * denotes $P < .05$ compared to the zero concentration of DCUKA or DCUK-OMe within a given glycine condition, while ** denotes $P < .05$ compared to the 0 glycine condition at a given concentration of DCUKA or DCUK-OMe. From FIG. 2 it is apparent that, in the absence of exogenous glycine, DCUKA and DCUK-OMe produce a concentration-related decrease in [3 H]dizocilpine binding that, upon addition of 1 μ M glycine, is significantly attenuated. These data suggest that the DCUK compounds can reduce the activation of NMDA receptor channels by antagonism of the strychnine-insensitive glycine site. Therefore, the DCUK compounds can be classified as antagonists which have actions at the strychnine-insensitive glycine site of the NMDA receptor.

EXAMPLE 3: Effects of DCUKA on NMDA-induced currents obtained from oocytes expressing recombinant NMDA receptors.

Oocytes were obtained from *Xenopus laevis* frogs (Nasco or Xenopus I) kept in aquarium tanks at 19-21°C, on a 12 hr light/dark cycle. Mature females were anesthetized by immersion for approximately 30 min in a 0.12% 3-aminobenzoic acid ethyl ester solution, a small incision was made in the abdominal wall and a piece of ovary was removed and placed in Modified Barth's solution (MBS; in mM) containing 88 NaCl, 1 KCl, 10 HEPES, 0.82 MgSO₄, 2.4 NaHCO₃, 0.91 CaCl₂, 0.33 Ca(NO₃)₂ (pH 7.5). To facilitate manual dissection of oocytes, a section of ovary was transferred from MBS to a hypertonic buffer containing 108 mM NaCl, 2 mM KCl, 2 mM EDTA, 10 mM

- 29 -

HEPES, pH 7.5 and theca and epithelial layers of mature oocytes (stages V and VI) were removed with surgical forceps. The follicular layer was removed by a 10 min immersion in 0.5 mg/ml of collagenase in buffer containing 83 mM NaCl, 2 mM KCl, 1 mM MgCl₂ and 5 mM HEPES.

5 Human NR1a, NR2A and NR2B cDNAs in pCDNA-1Amp were transformed and amplified in XL-1 Blue cells and purified with the MaxPrep Qiagen kit. Oocytes were injected with cDNA into the nucleus in the following concentrations: NR1a/2A cDNAs 0.75 ng/30 nl 1:1 ratio, NR1a/2B cDNAs 3.0 ng/30 nl 1:1 ratio. Injections were made with micropipettes (10 μ m tip diameter) connected to a Drummond micropipettor attached to a micromanipulator. After injection, oocytes were individually placed in wells of 96-well microtiter plates containing incubation medium (MBS supplemented with 10 mg/l streptomycin, 10,000 U/l penicillin G, 50 mg/l gentamicin, 2 mM sodium pyruvate, 0.5 mM theophylline) that had been sterilized by passage through a 0.2 mm filter. Oocytes were incubated at 19°C for 2 to 4 days after injection.

Oocytes were placed in a rectangular chamber (approximately 100 ml) and perfused (2 ml/min) with frog Ringer (in mM) containing 115 NaCl, 2.5 KCl, 1.8 CaCl₂, 10 HEPES (pH 7.2). Oocytes were impaled with two glass electrodes (0.5-10 M Ω) filled with 3 M KCl and clamped at -70 mV using a Warner Instruments (Hamden, CT) oocyte clamp (model OC-725C). A strip-chart recorder (Cole-Palmer Instrument Company) continuously plotted the clamping currents. Agonist solutions with or without DCUKA were applied for 20 sec at 5-10 min intervals. Each oocyte represents a single *n*. Control responses were always measured before and after addition of the DCUKA. The responses to agonist (NMDA) was averaged to account for run-down or run-up that normally occurs with glutamate receptors. Data are expressed as the % inhibition of the agonist response obtained in the absence of the drug.

FIG. 3A shows that DCUKA produced a concentration-dependent inhibition of currents generated by application of 100 μ M NMDA in the presence of 1 μ M glycine to oocytes expressing NR1a/NR2A recombinant receptors (IC₅₀=12.8 μ M) or 100 μ M NMDA in the presence of 0.3 μ M glycine to oocytes expressing NR1a/NR2B recombinant receptors (IC₅₀=20.7 μ M). The

concentration of glycine chosen was that which, in combination with NMDA, produced a half-maximal response in oocytes expressing the given NR1a/NR2 heteromer. These affinity estimates are in good agreement with those determined in the [³H]5,7-DCKA binding assay and demonstrate in a physiological system the antagonism of NMDA receptor function. The lower potency of DCUKA for NR1a/NR2B receptors is likely a result of the higher affinity of this subunit combination for glycine compared to NR1a/NR2A receptors (Williams, K., *et al.*, "SENSITIVITY OF THE N-METHYL-D-ASPARTATE RECEPTOR TO POLYAMINES IS CONTROLLED BY NR2 SUBUNITS," *Mol. Pharmacol.*, 45 803-809, 1994).

FIG. 3B-1 demonstrates that when the inhibition of NMDA (100 μ M)-induced currents by 50 μ M DCUKA was tested in the presence of increasing concentrations of added glycine, the amount of inhibition by DCUKA of NR1a/NR2B receptors was completely reversed at 10 μ M glycine. This demonstration provided further support that the DCUK compounds antagonize the NMDA receptor by competitively binding to the glycine site of the NMDA receptor composed of NR1a/NR2B subunits. However, the inhibition of NMDA-induced currents in oocytes expressing NR1a/NR2A receptors by 50 μ M DCUKA could not be overcome by glycine, even at a 100 μ M concentration. These data are consistent with a non-competitive antagonism by the DCUKA of NMDA receptor function when the receptors are comprised of NR1a/NR2A subunits. These actions of DCUKA on NMDA receptors comprised of NR1a/NR2A subunits contrast with those of the classic NMDA receptor glycine site antagonist (5,7-DCKA) (FIG. 3B-2), which competitively antagonizes NMDA receptors regardless of subunit composition.

EXAMPLE 4: Effects of DCUKA on sodium currents obtained from CHO cells stably expressing VSNaCs and the effect of DCUKA on calcium currents obtained from oocytes expressing voltage-sensitive calcium channels (VSCCs).

Chinese hamster ovary (CHO) cells stably expressing RSM (μ 1) sodium channels were studied using the patch clamp whole cell recording technique. CHO cells were grown to confluence in Dulbecco's Modified Eagle's Medium fortified with 15% FBS, 100 U/ml penicillin and 100 μ g/ml

- 31 -

streptomycin in a humidified incubator at 37°C and 5% CO₂, with medium changed every 2-3 days. Transfections with the plasmid pZem μ 1-2 were performed using the calcium phosphate coprecipitation method. After 24 hr of incubation with DNA, standard culturing conditions were resumed. After 3 days, stably transfected cells were selected with 400 μ g/ml geneticin. Transfected cells were grown to confluence and then plated on 35 mm culture dishes for 24-96 hr before the experiment.

An 8900 Dagan patch clamp amplifier with a 1 G Ω 8920 Dagan headstage was used in combination with a Nikon Diaphot inverted microscope. Micromanipulators were used to place the electrode onto the cell. Electrodes were pulled to a resistance of 1-2 M Ω . The external solution was (in mM) 132 NaCl, 4 KCl, 0.4 CaCl₂, 0.4 MgCl₂, 5 glucose, 20 sucrose and 5 HEPES, while the internal solution was 90 CsF, 60 CsCl, 11 NaCl, and 5 HEPES (pH 7.4). Pulse protocols were generated using a 486 PC computer running pCLAMP 5.0 (Axon Instruments, Foster City, CA). The cell was held at -100 mV, stepping to various depolarizing potentials (ranging from -80 to 100 mV in increments) for 9 ms, and then returning to the holding potential. Consecutive steps were carried out every 1.5 sec and the data were leak subtracted using the P/4 method, stepping negatively from the -100 mV holding potential. Peak currents were determined from these traces. DCUKA dissolved in 0.4% DMSO was added directly to the bath following seal formation and the data are expressed as the % of the initial peak current response obtained before drug addition. The results are the mean \pm S.D. of three separate preparations.

The DMSO vehicle, although producing an initial drop in current amplitude, produced no lasting effect, and the control current returned to pre-drug or vehicle levels (i.e., 3.3 ± 0.7 nA) within one minute of perfusion. The DCUKA-mediated decrement in current through VSNaCs in this preparation and the increasing inhibition of the response with successive depolarizations substantiate the data obtained with measures of [³H]BTX binding that the DCUKA is a use- and voltage-dependent inhibitor of VSNaCs. The data are shown in FIG. 4.

In other studies, Stage V and VI oocytes were prepared from *Xenopus laevis* and maintained using the procedures described in Example 3. Oocytes were injected with cRNA encoding the rabbit cardiac L-type VSCC α_{1c} , together with the ancillary subunits α_2/δ and β_{2c} in a 1:1:1 molar ratio.

- 5 Macroscopic currents were recorded 4-6 days following injection using the two electrode voltage clamp technique. During recording, oocytes were maintained at room temperature in a perfusion chamber and perfused (1 ml/min) continuously with a buffer containing (in mM) 100 LiCl, 10 HEPES, 10 HEDTA, 14 TEA-Cl, 0.015 CaCl₂, (effective free calcium concentration ~3 nM), pH 7.4 with TEA-
10 OH. The monovalent ion Li⁺ was used as the charge carrier rather than Ba²⁺ in these studies because high concentrations of divalent ions promoted precipitation of DCUKA.

- DCUKA was made up as a stock solution in DMSO and used in the studies at a concentration of 50 μ M, resulting in a final DMSO percentage of
15 0.25%. This concentration of DMSO enhanced Li⁺ currents to a small extent, however, this was controlled for by exchanging between solutions that were identical except for presence/absence of the drug itself. Pipettes were filled with 3 M KCl and had a typical resistance of 1.5 M Ω . Li⁺ currents were recorded using an OC-725B amplifier (Warner Instruments), filtered at 1 kHz (4-pole
20 Bessel filter, Warner Instruments) and sampled at 2 kHz. Voltage pulses of 250 ms duration were given every 15 sec. The holding potential was -80 mV and the test potential was -20 mV. Under these conditions, DCUKA produced a non-significant (less than 20%) decrement in the current through VSCCs (data not shown) arguing that the inhibition of VSNaC-mediated currents in CHO cells is
25 not a general inhibition of voltage-sensitive ion channel function.

EXAMPLE 5: Effects of (\pm)HA-966 and 7-Cl kynurenic acid on ethanol withdrawal-induced seizures in C57BL/6 mice.

- 30 Male C57BL/6 mice were housed individually. One group of mice were each given a measured amount of liquid diet (BioServ) containing 6.7% ethanol (v/v) and a second, control group of mice each received the same diet with maltodextrin substituted isocalorically for ethanol, as their sole nutrient

source for 7 days. A description of such a test can be found in Grant, K.A., *et al.*, "ETHANOL WITHDRAWAL SEIZURES AND THE NMDA RECEPTOR COMPLEX," Eur. J. Pharmacol., 176 289-296, (1990), the relevant disclosures of which are incorporated herein by reference. Pair-fed mice were given a volume of liquid
5 diet equal to the average volume that the ethanol-fed mice consumed on the previous day. This treatment regimen produces mice that are functionally tolerant to and physically dependent on ethanol. Beginning at 0700 hours on the eighth day of the diet, ethanol-containing diet was replaced with control liquid diet ("withdrawal").

10 Withdrawal seizure severity was assessed by measuring the incidence of handling-induced and spontaneous seizures, which were rated on a rating scale of 0 to 4, modified from a rating scale described by Grant, K.A., *et al.* in the above cited article. The rating scale was as follows: 0, little or no reaction; 1, slight jerkiness upon handling; 2, excitability increasing in magnitude
15 to a clonic-tonic seizure; 3, spontaneous or instantaneous clonic-tonic seizure; 4, death while in a seizure. The mice were rated for seizure severity at 2, 4, 6, 7, 8, 9, 10, 11, 12 and 24 hours after ethanol withdrawal. Groups of ethanol-fed mice were injected intraperitoneally at 0700, 1100 and 1400 hours with saline, 3, 10 or 17 mg/kg (\pm)HA-966 (FIG. 5A) or 10, 17 or 30 mg/kg 7-Cl kynurenic
20 acid (FIG. 5B) .

The results presented in FIG. 5A and FIG. 5B, respectively, are the median withdrawal scores of saline-injected (N=6) or drug-injected mice (N=7, each dose). From FIG. 5A and 5B it can be seen that treatment with (\pm)HA-966 or 7-Cl kynurenic acid did not significantly reduce seizure severity at
25 any dose or at any time after initiation of withdrawal ($P > .05$; Kruskal-Wallis ANOVA). Data obtained in the study of EXAMPLE 14 below additionally illustrates that (\pm)HA-966 at doses used in the unsuccessful attempts to prevent withdrawal seizures, produce signs of incoordination and ataxia.

Carbamazepine was also administered in doses of 17, 30, or 50
30 mg/kg at 0700, 1100, and 1400 hours on the day of withdrawal and no significant reduction of severity or the duration of the signs of withdrawal (data not shown) was noted.

- 34 -

EXAMPLE 6: Effects of DCUK-OMe on ethanol withdrawal-induced seizures in C57BL/6 mice.

Male C57BL/6 mice were fed ethanol in a liquid diet and the withdrawal seizure severity was assessed as described in EXAMPLE 5. Groups of ethanol-fed mice received a single injection (i.p.) of either vehicle (4% Tween-80, 0.5% carboxymethylcellulose in 0.9% saline) alone or of 100 mg/kg DCUK-OMe suspended in the vehicle administered at 0900 hours. The results are presented in FIG. 6A as the median withdrawal scores of vehicle-injected (N=14) or DCUK-OMe injected (N=6) mice in which * denotes $P < .05$, statistically compared to vehicle-injected mice, in the Mann-Whitney U test. FIG. 6B presents the same data as the total withdrawal score, defined as the area enclosed by the curve connecting median withdrawal scores plotted against time as in FIG. 6A. The mean total withdrawal scores \pm SEM for the vehicle-injected group and DCUK-OMe-injected groups are plotted in which * denotes $P < .05$, statistically compared to vehicle-injected mice, by the Student t-test.

These data suggest that, unlike agents which are solely antagonists of the glycine site of the NMDA receptor ((\pm) HA-966 and 7-Cl kynurenic acid), or agents that are primarily antagonists of VSNaCs with no affinity for the glycine site of the NMDA receptor, *e.g.*, carbamazepine (see, for example, McCabe, R.T., *et al.*, cited in the notes to Table 1A) and the data in Table 1A, DCUK-OMe, a combined glycine site antagonist and VSNaC blocker, reduces ethanol withdrawal severity.

EXAMPLE 7: Anxiolytic effects of DCUK-OMe measured in Swiss-Webster mice.

The anxiolytic effect of the DCUK-OMe was studied in naive Swiss-Webster mice using an elevated plus-maze apparatus. The plus-shaped maze consists of two arms which are open to the environment (about 30 x 5 cm) and two arms with side and end walls (about 30 x 5 x 15 cm). The arms are connected to a central area (about 5 x 5 cm) and the plus-maze is elevated from the floor to a height of about 50 cm.

- 35 -

All tests were conducted in a sound-attenuated room under low intensity light (25 Watt). Mice were allowed a 30-minute habituation to the darkened testing room after which the mice were placed individually in the central area of the plus-maze facing one of the open arms, and were then allowed to move freely among the open and closed arms. A trained observer blind to the treatment conditions scored the number of entries into open arms, the number of entries into closed arms, the number of entries into the central area, the number of rears, and the number of grooming episodes over a 5-minute period. Between tests, the maze was wiped clean. The percentage open arm entries was calculated for each animal and used as a measure of the anxiolytic/anxiogenic effects of drug treatment. In addition, the total number of entries made into either open or closed arms was recorded as a measure of drug effects on locomotor activity.

Mice were injected with either vehicle (5% Tween-80, 20% Intralipid) or 100 mg/kg or 500 mg/kg DCUK-OMe suspended in the vehicle about 90 minutes before testing in the plus-maze apparatus. Data were expressed as the percent increase in open arm entries of the drug treated animals compared to vehicle-injected mice. The results obtained are plotted in Figure 7. Data were analyzed using a one-way ANOVA on ranks. In Figure 7, * denotes $P < .05$ compared to the vehicle injected mice.

From this data, it is apparent that DCUK-OMe has anxiolytic activity and supports the use of this compound in treating anxiety resulting during drug withdrawal and other anxiety states. It should also be noted that mice receiving injections of either dose of DCUK-OMe did not show any increase in total arm entries compared to vehicle, demonstrating the lack of unwanted stimulatory effects of the DCUK compounds.

EXAMPLE 8: Effect of DCUK-OMe on audiogenic seizures measured in DBA/2J mice.

Male DBA/2J mice (20-22 days old; 8-12g) were used to evaluate the effects of DCUK-OMe in an animal model of partial seizures. A description of this test for audiogenic seizures can be found in Engstrom, F.L., *et al.*, "SEIZURE SUSCEPTIBILITY IN DBA AND C57 MICE: THE EFFECTS OF VARIOUS

- 36 -

CONVULSANTS," *Epilepsia*, 29 389-395 (1988), the relevant disclosures of which are incorporated herein by reference. Mice were injected with either vehicle (5% Tween-80, 20% Intralipid) or 100 mg/kg or 500 mg/kg DCUK-OMe suspended in the vehicle about 90 minutes before being placed into a testing chamber having a size of about 6 inches (about 15.2 cm) diameter x about 20 inches (about 50.8 cm) height enclosed in a sound-attenuated box. After a 15-20 second habituation period, a high-intensity auditory stimulus (ringing doorbell, 12-16 kHz, 109db) was activated for 30 seconds or until tonic hindlimb extension occurred. The seizure response in these mice was characterized by a progression of a wild running behavior, followed by loss of righting and clonus of the forelimbs, followed by tonic hindlimb extension, and finally respiratory arrest. The number of mice showing each response was recorded. Figure 8 shows the frequency of clonic seizures following administration of the vehicle, 100 mg/kg DCUK-OMe, and 500 mg/kg DCUK-OMe (n=10-20 per group) as described above. Data were analyzed by the Fisher Exact Test. In Figure 8, * denotes $P < .05$ compared to vehicle injected mice. These data indicate that the DCUK compounds provide protection from convulsions arising from conditions other than drug withdrawal.

20 EXAMPLE 9: Effect of MeO-DCUKA on kainate (KA)-induced seizures.

Groups of male C57BL/6 mice were separately given either the vehicle (4% Tween-80, 0.5 carboxymethylcellulose), or 100 mg/kg MeO-DCUKA suspended in the vehicle administered either intraperitoneally (i.p.) or orally (p.o.) about 30 minutes before receiving an injection of kainate (KA) (30 mg/kg, i.p.) and then were observed for the next 4 hours for the presence or absence of KA-induced seizure-related behaviors. KA-induced seizure-induced behavior includes immobility ("staring"), forepaw clonus, clonic-tonic seizures, and death of the animals. The results are shown in Table 2 below.

- 37 -

Table 2

Mice	vehicle/KA (i.p.)	MeO-DCUKA (100 mg/kg, i.p.)	MeO-DCUKA (100 mg/kg, p.o)
	# protected/ # tested		
5	4/11 (36%)	3/6 (50%)	3/4 (75%)

From the data in Table 2, it can be concluded that pretreatment with MeO-DCUKA, administered by either intraperitoneal or oral routes substantially protected the animals from KA-induced seizures.

EXAMPLE 10: Effects of DCUK-OMe on glutamate-induced excitotoxic cell death in primary cultures of rat cerebellar granule cells.

Primary cultures of cerebellar granule cells were prepared from 6- to 8-day old Sprague-Dawley rats. A description of this procedure can be found in Iorio, K.R., *et al.*, "CHRONIC EXPOSURE OF CEREBELLAR GRANULE CELLS TO ETHANOL RESULTS IN INCREASED N-METHYL-D-ASPARTATE RECEPTOR FUNCTION," *Mol. Pharmacol.*, 41 1142-1148 (1992), the relevant disclosures of which are incorporated herein by reference. The cultures were maintained in plates containing 24 wells of 1 ml each. Culture density was about 1.5×10^6 cells/ml. Cell viability was assayed after 7-8 days in culture by the production of fluorescein, formed from fluorescein diacetate by esterases present in living cells. A description of this assay can be found in Iorio, K.R., *et al.*, "GLUTAMATE-INDUCED NEUROTOXICITY IS INCREASED IN CEREBELLAR GRANULE CELLS EXPOSED CHRONICALLY TO ETHANOL," *Eur. J. Pharmacol.*, 248 209-212 (1993), the relevant disclosures of which are incorporated herein by reference.

Cells were washed with Mg^{2+} -free Locke's buffer, and then exposed to glutamate alone or glutamate in the presence of 10, 30, or 100 μM DCUK-OMe at 25°C for 30 minutes. After glutamate exposure, cells were washed twice with buffer and returned to conditioned medium for 24 hours before the fluorescein assay was performed. For each study, the fluorescence value of a

- 38 -

control culture (*i.e.*, not exposed to glutamate) was set to 35,000 fluorescence units, and fluorescence values in all other cultures determined using the same spectrofluorometric settings were normalized to that value. One measurement corresponds to the contents of one 1 ml culture well. The data are then
5 expressed as the percent cell death relative to the control cultures.

The results obtained are shown in FIG. 9 as the mean \pm SEM in which * denotes $P < .05$, compared to glutamate alone, (ANOVA). From FIG. 9, it can be seen that DCUK-OMe can block glutamate-induced cell death in a concentration-dependent manner, affording complete protection at 100 μ M.
10 These data suggest that the DCUK compounds by virtue of their functional antagonist properties at the NMDA receptor complex through a specific action at the associated strychnine-insensitive glycine site exhibit neuroprotective effects against excitotoxic cell death. In addition, as the influx of Na^+ secondary to the depolarization induced by glutamate is thought to contribute to cell death. See,
15 for example, Choi, D.W., "EXCITOTOXIC CELL DEATH," *J. Neurobiol.*, 23 1261-1279 (1992), blockade of VSNaCs by the DCUK compounds may afford additional neuroprotective properties.

20 EXAMPLE 11: Effect of MeO-DCUKA on KA-induced increase in heat shock protein (HSP72) in the hippocampus of C57BL/6 mice.

In animal models where NMDA receptor-mediated excitotoxic mechanisms have been identified (*e.g.*, KA-induced seizures), an early (24 hours
25 after insult) increase in the 72 kDa heat shock protein (HSP72) levels is detected in brain regions that demonstrate severe neuronal damage and ultimate cell loss. See, for example, Gonzales, M.F. *et al.*, "HEAT SHOCK PROTEINS AS MARKERS OF NEURAL INJURY," *Mol. Brain Res.*, 6 93-100 (1989), the relevant portions of which are incorporated herein by reference.

30 Groups of male C57BL/6 mice separately received either (1) no injections (Naive), (2) KA injections (30 mg/kg, *i.p.*), (3) 100 mg/kg MeO-DCUKA administered intraperitoneally, or (4) a pretreatment of 100 mg/kg MeO-DCUKA administered (vehicle as in Example 9) intraperitoneally about 30

- 39 -

minutes before receiving an injection of KA (30 mg/kg, i.p.). All of the mice were killed 24 hours later, their brains removed and the hippocampus dissected. HSP72 protein levels were determined in sodium dodecylsulfate (SDS)-solubilized hippocampal lysates by SDS-PAGE electrophoretic separation and subsequent Western blot analysis using antibodies specific for HSP72/73 proteins. Immunoreactive bands were visualized on film using enhanced chemiluminescence and quantitated by image analysis.

The data obtained are graphed in FIG. 10 where * denotes $P < .01$, statistically compared to all other groups, (ANOVA). From FIG. 10, it can be seen that KA injections produced a significant increase in HSP72 protein levels that was prevented by the 30 min pre-injection pretreatment with 100 mg/kg MeO-DCUKA as described above. These data suggest that MeO-DCUKA affords protection against neuronal injury associated with the excitotoxin, KA.

EXAMPLE 12: Comparison of the effects of carbamazepine and benzodiazepine with DCUK compounds on the production of ataxia/incoordination.

Naive Swiss-Webster mice were trained to remain on an accelerating rotarod (diameter 3 cm, 0-30 rpm over 5 min) for six consecutive trials. A description of this test for the acute incoordinating/ataxic effects of sedative/hypnotic drugs such as ethanol can be found in Hoffman, P.L., *et al.*, "EFFECT OF AN IMIDAZOBENZODIAPEZINE, Ro15-4513, ON THE INCOORDINATION OF HYPOTHERMIA PRODUCED BY ETHANOL AND PENTOBARBITAL," *Life Sci.*, **41** 611-619 (1987), the relevant disclosures of which are incorporated herein by reference.

The amount of time the mice remained on the rotarod during their last trial was used as their "base-line" score. The mice were then injected (i.p.) with either vehicle (5% Tween-80, 20% Intralipid) (n=10), or 1mg/kg diazepam (DZP) in vehicle (n=10), or 50 mg/kg carbamazepine (CBZ) (n=5) in vehicle or 100 or 500 mg/kg DCUK-OMe in vehicle. The length of time the mice remained on the rotarod was redetermined at 15, 30, 60, 90, and 120 min after drug injection (i.p.). Results for each mouse at the 30 minute time point were

- 40 -

expressed as a ratio (percentage) of their pre-injection base-line time on the rotarod.

The results obtained are plotted in FIG. 11 in which * denotes $P < .05$ (repeated measures ANOVA following arcsine transformation of percentage scores) compared to vehicle.

From FIG. 11, it can be seen that mice treated with 50 mg/kg CBZ (a total dose that did not reduce the severity of ethanol withdrawal) were impaired in their ability to remain on the rotarod after the injection.

In contrast, it was noted that naive Swiss-Webster mice administered either 100 mg/kg or 500 mg/kg DCUK-OMe (i.p.) as described above, were able to remain throughout the testing period. These data suggest that DCUK-OMe did not exhibit the same ataxic/incoordinating effects at doses which afford both anticonvulsant and neuroprotective action against the excitotoxin KA and protect against ethanol withdrawal seizures (EXAMPLE 6). On the other hand, it was found that another agent commonly used to treat withdrawal, diazepam (even at a dose of 1 mg/kg), produced significant incoordination of mice on the rotarod. In addition, injection of mice with 50 mg/kg carbamazepine ($n=5$) also produced significant impairment of ability of mice to remain on the rotarod.

EXAMPLE 13: DCUK compounds do not potentiate the sedative/anesthetic effects of ethanol as do other agents (i.e., benzodiazepines) used for treatment of alcohol withdrawal.

Swiss-Webster mice were pretreated (i.p.) with 100 mg/kg DCUK-OMe or 1 mg/kg diazepam (DZP) (in 5% Tween-80, 20% Intralipid) 30 minutes before receiving an i.p. administration of ethanol (either 2.3 or 3.2 g/kg, 20% v/v in saline.). The duration of the ethanol-induced loss of righting reflex (defined as the inability of the mouse to right itself when placed on its back in a trough) was measured. The 2.3 g/kg dose of ethanol given alone did not produce a loss of righting reflex while the 3.2 g/kg produced a 20-minute loss of righting reflex. The data shown in FIG. 12 demonstrate a significant ($*P < 0.05$) enhancement of the duration of loss by righting reflex (LORR) by DZP and no

- 41 -

significant enhancement by DCUK-OMe. Since withdrawal signs are many times evident in individuals whose blood ethanol levels are dropping but are far from zero, the DCUK compounds would have an advantage over DZP in that the CNS depressant effects of ethanol would not be accentuated by DCUK compounds if
5 the DCUK compounds are used in an alcohol-intoxicated individual.

EXAMPLE 14: The effects of the glycine site antagonist
(\pm)HA-966 on the production of ataxia/incoordination.

10 Naive C57BL/6 mice were trained to remain on an accelerating rotarod (diameter 3 cm, 0-30 rpm over 5 min) for six consecutive trials. A description of this test for the acute incoordinating/ataxic effects of sedative/hypnotic drugs such as ethanol can be found in Hoffman, P. L., *et al.*, Life Sciences, 41 611-619 (1987), the relevant disclosures of which are
15 incorporated herein by reference.

The amount of time the mice remained on the rotarod during their last trial was used as their "base-line" score. The mice were then treated with saline (n=10) or 50 mg/kg (\pm)HA-966 (n=5). The length of time the mice remained on the rotarod was redetermined at 15, 30, 60, 90, and 120 min after
20 drug injection (i.p.). Results for each mouse at each time point were expressed as a ratio (percentage) of their pre-injection base-line time.

The results obtained are plotted in FIG. 13 in which * denotes $P < .05$ compared to (\pm)HA-966 treated mice (repeated measures ANOVA following arcsine transformation of percentage scores).


25 From FIG. 13, it can be seen that mice treated with 50 mg/kg (\pm)HA-966 (a total dose that did not reduce the severity of ethanol withdrawal) were impaired in their ability to remain on the rotarod at all time points tested after the injection. These data indicate that this glycine site antagonist has significant ataxic/incoordinating effects at doses that do not afford protection
30 against ethanol withdrawal seizures.

- 42 -

CLAIMS

WE CLAIM:

1. A method suitable for treating withdrawal syndromes manifested in a patient suffering withdrawal symptoms and/or withdrawal-induced
 5 brain damage which comprises administering an effective ameliorating amount of a compound having the general formula (I):



15

a tautomer thereof, a pharmacologically acceptable ester, amide, salt, ether, or an acid addition salt thereof;

wherein R¹ represents hydrogen or an alkyl group of 1 to 6 carbon atoms;

20

R² and R³ each independently represent phenyl which may be unsubstituted or substituted one or more times with substituents selected from the group consisting of alkoxy, cycloalkoxy, alkyl, and cycloalkyl groups containing up to 6 carbon atoms, hydrogen, hydrocarbon selected from the group consisting of straight chain, branched, cyclic, and heterocyclic groups containing up to 18
 25 carbon atoms, halogen, cyano, trifluoromethyl, nitro, -OR^a, -SR^a, -NR^aR^b, NR^aCOR^b, -NR^aCO₂R^b, -NR^aSO₂R^b, -NRⁱCZNR^aR^b, -CO₂, or -CONR^aR^b; wherein R^a, R^b, Rⁱ each independently represent hydrogen or hydrocarbon as described above and can be the same or different and Z represents oxygen, sulphur, or a group of formula =N,E; wherein E represents hydrocarbon as
 30 described above or an electron-withdrawing group; or

R² and R³ together with the intervening carbon atom represent carbonyl (C=O), thiocarbonyl (C=S), imino (C=N,R^a), oximino (C=N,OR^a),

- 43 -

or a 3- to 8-membered ring containing from zero to 4 hetero-atoms selected from the group consisting of oxygen, nitrogen, sulphur and phosphorus; wherein R¹ represents hydrogen or hydrocarbon as described above;

wherein each of the R² and R³ substituents can be the same or
5 different; and

X represents halogen and each of the 5, 7, substituents can be the same or different.

2. The method of claim 1 wherein in the compound of formula
(I) each of the X substituents is chloro, R¹ is hydrogen, and R² and R³ each is a
10 phenyl group.

3. The method of claim 1 wherein in the compound of formula
(I) each of the X substituents is chloro, R¹ is an alkyl group having 1 to 3 carbon
atoms, and R² and R³ each is a phenyl group.

4. The method of claim 1 wherein in the compound of formula
(I) each of the X substituents is chloro, R¹ is hydrogen, one of R² and R³ is an
15 unsubstituted phenyl group and the other is phenyl having an alkoxy substituent
having 1 to 3 carbon atoms.

5. The method of claim 1 wherein the treatment is for alcohol
withdrawal.

20 6. The method of claim 1 wherein the treatment is for drug
withdrawal.

7. The method of claim 1 wherein the treatment is for
withdrawal-induced brain damage.

8. The method of claim 1 wherein the compound is
25 administered in an amount of up to about 500 mg/kg of body weight.

9. The method of claim 1 wherein the amount of compound
administered is in the range of about 10 to about 100 mg/kg of body weight.

10. A composition suitable for use in the method of claim 1
containing a compound selected from the group consisting of a compound of
30 formula (I), a tautomer, or pharmaceutically acceptable ester, amide, salt, ether
and addition salt thereof, in an amount of about 0.1 to about 95 weight percent
and a pharmaceutically acceptable vehicle.


- 44 -

11. The composition of claim 10 wherein the compound is selected from the group consisting of (N,N-diphenyl)-4-ureido-5,7-dichloro-2-carboxy-quinoline, (N,N-diphenyl)-4-ureido-5,7-dichloro-2-carboxy-quinoline methyl ester, and N-phenyl, N-[2-methoxy]phenyl)-4-ureido-5,7-dichloro-2-carboxy-quinoline.

12. A compound suitable for treating withdrawal syndromes manifested in a patient suffering withdrawal symptoms and/or withdrawal-induced brain damage which comprises administering an effective ameliorating amount of a compound having the general formula (I):

10

15



a tautomer thereof, a pharmacologically acceptable ester, amide, salt, ether, or an acid addition salt thereof;

wherein R¹ represents hydrogen or an alkyl group of 1 to 6 carbon atoms;

R² and R³ each independently represent phenyl which may be unsubstituted or substituted one or more times with substituents selected from the group consisting of alkoxy, cycloalkoxy, alkyl, and cycloalkyl groups containing up to 6 carbon atoms, hydrogen, hydrocarbon selected from the group consisting of straight chain, branched, cyclic, and heterocyclic groups containing up to 18 carbon atoms, halogen, cyano, trifluoromethyl, nitro, -OR^a, -SR^a, -NR^aR^b, NR^aCOR^b, -NR^aCO₂R^b, -NR^aSO₂R^b, -NRⁱCZNR^aR^b, -CO₂, or -CONR^aR^b; wherein R^a, R^b, Rⁱ each independently represent hydrogen or hydrocarbon as described above and can be the same or different and Z represents oxygen,

- 45 -

sulphur, or a group of formula =N,E; wherein E represents hydrocarbon as described above or an electron-withdrawing group; or

R² and R³ together with the intervening carbon atom represent carbonyl (C=O), thiocarbonyl (C=S), imino (C=N,R^a), oximino (C=N,OR^a),
5 or a 3- to 8-membered ring containing from zero to 4 hetero-atoms selected from the group consisting of oxygen, nitrogen, sulphur and phosphorus; wherein R^a represents hydrogen or hydrocarbon as described above;

wherein each of the R² and R³ substituents can be the same or different; and

10 X represents halogen and each of the 5, 7, substituents can be the same or different.

13. A compound of claim 12 wherein each of the X substituents is chloro, R¹ is hydrogen, and R² and R³ each is a phenyl group.

14. A compound of claim 12 wherein each of the X substituents
15 is chloro, R¹ is an alkyl group having 1 to 3 carbon atoms, and R² and R³ each is a phenyl group.

15. A compound of claim 12 wherein each of the X substituents is chloro, R¹ is hydrogen, one of R² and R³ is an unsubstituted phenyl group and the other is phenyl having an alkoxy substituent having 1 to 3 carbon atoms.

20 16. A method of preparing a compound of claim 12 comprising the steps of:

a) reacting 3,5-dichloroaniline and dimethyl acetylenedicarboxylate to form dimethylanilinofumarate;

25 b) cyclizing the dimethylanilinofumarate with diphenyl ether to form 4(1H)-quinolone-2-carboxylate;

c) aminating the 4(1H)-quinolone-2-carboxylate with chlorosulphonyl isocyanate in acetonitrile to form a 4-aminated derivative thereof; and

30 d) acylating the 4-aminated derivative with diphenyl carbamoyl chloride to form (N,N-diphenyl)-4-ureido-5,7-dichloro-2-carboxy-quinoline methyl ester.

- 46 -

17. The method of claim 16 further including the step of:
- e) hydrolyzing the (N,N-diphenyl)-4-ureido-5,7-dichloro-2-carboxy-quinoline methyl ester to (N,N-diphenyl)-4-ureido-5,7-dichloro-2-carboxy-quinoline.
- 5 18. The product of the method of claim 16.
19. The product of the method of claim 17.
20. A compound of claim 12 characterized by exhibiting an affinity for both the strychnine insensitive glycine binding site on the N-methyl-D-aspartate receptor and voltage dependent sodium channels when
- 10 administered systemically to a patient subject to or manifesting neuroexcitability disorders.
21. A method suitable for treating a patient to prevent or ameliorate neuroexcitability disorders comprising administering to a patient in need of such treatment an antagonist compound exhibiting affinity for both the
- 15 strychnine-insensitive glycine binding site on N-methyl-D-aspartate receptor and voltage dependent sodium channels.
22. The method of claim 21 wherein the compounds is selected from the group consisting of N-substituted-4-ureido-5,7-dihydro-2-carboxy quinoline, a tautomer thereof, a pharmacologically acceptable ester, amide, salt,
- 20 ether and addition salt thereof.
23. The method of claim 20 wherein the compound is selected from the group consisting of (N,N-diphenyl)-4-ureido-5,7-dichloro-2-carboxy-quinoline, (N,N-diphenyl)-4-ureido-5,7-dichloro-2-carboxy-quinoline methyl ester, and N-phenyl, N-[2-methoxy]phenyl)-4-ureido-5,7-dichloro-2-carboxy-quinoline.

1/14




FIG. 1A




FIG. 1B

SUBSTITUTE SHEET (RULE 26)

2/14




FIG. 2

3/14




FIG. 3A

4/14




FIG. 3B-1




FIG. 3B-2

5/14




FIG. 4

6/14




FIG. 5A




FIG. 5B

7/14




FIG. 6B




FIG. 6A

8/14




FIG. 7

9/14




FIG. 8

10/14




FIG. 9

11/14




FIG. 10

12/14




FIG. 11

13/14




FIG. 12




FIG. 13

Please type a plus sign (+) inside this box → ☐

PTO/SB/01 (12-97)

Approved for use through 9/30/00. OMB 0651-0032
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION (37 CFR 1.63) <input checked="" type="checkbox"/> Declaration Submitted with Initial Filing OR <input type="checkbox"/> Declaration Submitted after Initial Filing (surcharge (37 CFR 1.16 (e)) required)	Attorney Docket Number	TBK-102-USN
	First Named Inventor	Tabakoff
	COMPLETE IF KNOWN	
	Application Number	/
	Filing Date	
	Group Art Unit	
	Examiner Name	

As a below named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

COMPOUNDS, COMPOSITIONS AND METHOD SUITABLE FOR AMELIORATION OF WITHDRAWAL SYNDROMES AND WITHDRAWAL INDUCED BRAIN DAMAGE

the specification of which (Title of the Invention)

☐ is attached hereto
OR
☒ was filed on (MM/DD/YYYY) **June 5, 1998** as United States Application Number or PCT International

Application Number **PCT/US98/11312** and was amended on (MM/DD/YYYY) (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached?	
				YES	NO
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

☐ Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto:

I hereby claim the benefit under 35 U.S.C. 119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date (MM/DD/YYYY)	<input type="checkbox"/> Additional provisional application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.
60/048,848	06/06/97 (June 6, 1997)	

[Page 1 of 2]

Burden Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/01 (12-97)
Approved for use through 9/30/00. OMB 0651-0032
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION — Utility or Design Patent Application

I hereby claim the benefit under 35 U.S.C. 120 of any United States application(s), or 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application or PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	Parent Patent Number (if applicable)

☐ Additional U.S. or PCT international application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

As a named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

☐ Customer Number

OR

☐ Registered practitioner(s) name/registration number listed below

Place Customer
Number Bar Code
Label here

Name	Registration Number	Name	Registration Number
Arne M. Olson	30,203	Michael A. Hierl	29,807
Dolores T. Kenney	31,269	Talivaldis Cepuritis	20,818
Seymour Rothstein	19,369	Daniel J. Deneufbourg	33,675

☒ Additional registered practitioner(s) named on supplemental Registered Practitioner Information sheet PTO/SB/02C attached hereto.

Direct all correspondence to: ☐ Customer Number or Bar Code Label

OR ☒ Correspondence address below

Name	TALIVALDIS CEPURITIS		
Address	OLSON & HIERL, LTD.		
Address	20 NORTH WACKER DRIVE, 36TH FLOOR		
City	CHICAGO	State	IL
ZIP	60601		
Country	US	Telephone	(312) 580-1180
Fax	(312) 580-1189		

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name of Sole or First Inventor:

☐ A petition has been filed for this unsigned inventor

Given Name (first and middle (if any))		Family Name or Surname		
Boris		TABAKOFF		
Inventor's Signature	B. Tabakoff		Date 7/14/98	
Residence: City	Elizabeth IL	State	IL	
Country	US		Citizenship	US
Post Office Address	1352 East Schappville Road			
Post Office Address				
City	Elizabeth	State	IL	
ZIP	61028		Country	US

☒ Additional inventors are being named on the 1 supplemental Additional Inventor(s) sheet(s) PTO/SB/02A attached hereto

Please type a plus sign (+) inside this box → +

PTO/SB/02A (3-97)
Approved for use through 9/30/98. OMB 0651-0032
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION

ADDITIONAL INVENTOR(S)
Supplemental Sheet
Page 1 of 1

Name of Additional Joint Inventor, if any:				<input type="checkbox"/> A petition has been filed for this unsigned inventor			
Given Name (first and middle [if any])				Family Name or Surname			
<u>Lawrence</u>				<u>SNELL</u>			
Inventor's Signature		<u>Laurence D. Snell</u>		Date		<u>7/14/98</u>	
Residence: City		<u>Aurora</u> <u>CO</u>		State		<u>CO</u> Country <u>US</u> Citizenship <u>US</u>	
Post Office Address <u>1565 South Paris Court</u>							
Post Office Address							
City		<u>Aurora</u>		State		<u>CO</u> ZIP <u>80012</u> Country <u>US</u>	
Name of Additional Joint Inventor, if any:				<input type="checkbox"/> A petition has been filed for this unsigned inventor			
Given Name (first and middle [if any])				Family Name or Surname			
<u>Paula L.</u>				<u>HOFFMAN</u>			
Inventor's Signature		<u>Paula L. Hoffman</u>		Date		<u>7/14/98</u>	
Residence: City		<u>Denver</u> <u>CO</u>		State		<u>CO</u> Country <u>US</u> Citizenship <u>US</u>	
Post Office Address <u>1633 Ivanhoe</u>							
Post Office Address							
City		<u>Denver</u>		State		<u>CO</u> ZIP <u>80220</u> Country <u>US</u>	
Name of Additional Joint Inventor, if any:				<input type="checkbox"/> A petition has been filed for this unsigned inventor			
Given Name (first and middle [if any])				Family Name or Surname			
Inventor's Signature				Date			
Residence: City				State		Country	
Post Office Address							
Post Office Address							
City				State		Country	

Burden Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

